[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO1995002610A1 - Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis - Google Patents

Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis Download PDF

Info

Publication number
WO1995002610A1
WO1995002610A1 PCT/US1994/000589 US9400589W WO9502610A1 WO 1995002610 A1 WO1995002610 A1 WO 1995002610A1 US 9400589 W US9400589 W US 9400589W WO 9502610 A1 WO9502610 A1 WO 9502610A1
Authority
WO
WIPO (PCT)
Prior art keywords
xaa
leu
lys
glu
arg
Prior art date
Application number
PCT/US1994/000589
Other languages
French (fr)
Inventor
John L. Krstenansky
John J. Nestor, Jr.
Teresa L. Ho
Brian H. Vickery
Chinh T. Bach
Original Assignee
Syntex (U.S.A.) Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1993/006465 external-priority patent/WO1994001460A1/en
Application filed by Syntex (U.S.A.) Inc. filed Critical Syntex (U.S.A.) Inc.
Publication of WO1995002610A1 publication Critical patent/WO1995002610A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to novel analogs of parathyroid hormone and parathyroid hormone related peptide, their synthesis by solid phase and recombinant techniques, and their use for increasing bone mass in mammalian subjects.
  • Osteoporosis is the most common form of metabolic bone disease and may be considered the symptomatic, fracture stage of bone loss
  • osteoporosis Although osteoporosis may occur secondary to a number of underlying diseases, 90% of all cases appear to be idiopathic.
  • Postmenopausal women are particularly at risk for idiopathic osteoporosis (postmeno-pausal or Type I osteoporosis).
  • Another high risk group for idiopathic osteoporosis is the elderly of either sex (senile or Type II osteoporosis).
  • Osteoporosis has also been related to corticosteroid use, immobilization or extended bed rest, alcoholism, diabetes, gonadotoxic chemotherapy, hyperprolactinemia, anorexia nervosa, primary and secondary amenorrhea, and oophorectomy.
  • osteoporosis In the various forms of osteoporosis, bone fractures, which are the result of bone loss that has reached the point of mechanical failure, frequently occur. Postmenopausal osteoporosis is characterized by fractures of the wrist and spine, while femoral neck fractures seem to be the dominant feature of senile osteoporosis.
  • the mechanism by which bone is lost in osteoporotics is believed to involve an imbalance in the process by which the skeleton renews itself.
  • bone remodeling This process has been termed bone remodeling. It occurs in a series of discrete pockets of activity. These pockets appear spontaneously within the bone matrix on a given bone surface as a site of bone resorption.
  • Osteoclasts bone dissolving or resorbing cells
  • Osteoclasts are responsible for the resorption of a portion of bone of generally constant dimension. This resorption process is followed by the appearance of osteoblasts (bone forming cells) which then refill with new bone the cavity left by the osteoclasts.
  • osteoporotics In a healthy adult subject, the rate at which osteoclasts and osteoblasts are formed is such that bone formation and bone resorption are in balance. However, in osteoporotics an imbalance in the bone remodeling process develops which results in bone being lost at a rate faster than it is being made. Although this imbalance occurs to some extent in most individuals as they age, it is much more severe and occurs at a younger age in postmenopausal osteoporotics or following oophorectomy.
  • osteoclasts Daily subcutaneous injections of hPTH(1-34) completely reversed the loss of trabecular bone and resulted in amounts of trabecular bone exceeding that of sham operated controls. The number of osteoblasts increased and the number of osteoclasts decreased.
  • the mammalian parathyroid hormones e.g. human (hPTH), bovine (bPTH), and porcine (pPTH)
  • hPTH human
  • bPTH bovine
  • pPTH porcine
  • Biological activity is associated with the N-terminal portion, with residues (1-34) apparently the minimum required.
  • the N-terminal segment of human PTH differs from the
  • PTH The primary function of PTH is to elicit the adaptive changes that serve to maintain a constant concentration of Ca 2+ in the extracellular fluid.
  • PTH acts on the kidneys to increase tubular reabsorption of Ca 2+ from the urine, as well as stimulating the conversion of calcifediol to calcitriol, which is responsible for absorption of Ca 2+ from the
  • PTH acts on bone to increase the rate of resorption of Ca 2+ and phosphate.
  • PTH stimulates the rate of bone resorption by osteoclasts, increases the rate of differentiation of mesenchymal cells to osteoclasts, and prolongs the half life of these latter cells .
  • With prolonged action of PTH the number of bone forming osteoblasts is also increased; thus, the rate of bone turnover and remodeling is enhanced.
  • individual osteoblasts appear to be less active than normal.
  • PTHrp Parathyroid hormone-related peptide
  • a 140+ amino acid protein and fragments thereof, reproduce the major biological actions of PTH.
  • PTHrp is elaborated by a number of human and animal tumors and other tissues and may play a role in hypercalcemia of malignancy.
  • the sequence of hPTHrp (1-34) is as follows: Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile 1 5 10 15
  • sequence homology between hPTH and hPTHrp is largely limited to the 13 N-terminal residues, 8 of which are identical; only 1 of 10 amino acids in the (25-34) receptor binding region of hPTH is conserved in hPTHrp. Conformational similarity may underIle the common activity.
  • This invention provides synthetic polypeptide analogs of parathyroid hormone (PTH) , parathyroid hormone related peptide (PTHrp) , and of the physiologically active truncated homologs and analogs of PTH and PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic cx-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:
  • this invention provides analogs of PTH, PTHrp, and the physiologically active truncated analogs and homologs of PTH and
  • amino acid residues (22-31) form an amphipathic ⁇ -helix, the sequence of said residues (22-31) selected from: a) Xaa 1 Xaa 2 Leu Xaa 4 Xaa 5 Leu Xaa 7 Xaa 8 Xaa 9 Xaa 10 wherein
  • Xaa 1 and Xaa 4 are independently Glu, Glu(OCH 3 ), His, or Phe; Xaa 2 is Leu or
  • Xaa 5 is Lys or His
  • Xaa 7 and Xaa 10 are independently Leu or Ile
  • Xaa 8 is
  • Xaa 9 is Lys or Glu (SEQ ID NO:26); b) Xaa 1 Xaa 2 Leu Xaa 4 Arg Leu Leu Xaa 8 Arg Leu wherein
  • Xaa 1 and Xaa 4 are independently Glu, Glu(OCH 3 ), His, or Phe; Xaa 2 is Leu or Phe; Xaa 8 is Glu, Lys, or Lys (COCR-PEGX) and PEGX is a poly- (ethylene glycol methyl ether) radical of molecular
  • this invention provides analogs of PTH, PTHrp, and the physiologically active truncated analogs and homologs of PTH and PTHrp, or salts thereof, of the formula:
  • Xaa 1 is absent or is Ala
  • Xaa 2 is absent or is Val
  • Xaa 3 is absent or is Ser
  • Xaa 4 is absent or is Glu or Glu (OCH-);
  • Xaa 5 is absent or is His or Ala
  • Xaa 6 is absent or is Gln;
  • Xaa 7 is absent or is Leu;
  • Xaa 10 and Xaa 17 are independently Asp or Asp (OCH 3 );
  • Xaa 11 is Lys, Arg, or Leu;
  • Xaa 13 is Lys, Arg, Tyr, Cys, Leu, Cys (CH 2 CONH (CH 2 ) 2 NH (biotinyl) ) , Lys (7-dimethylamino-2 -oxo-2H-l-benxopyran-4 -acetyl) , or Lys (dihydrocinnamoyl);
  • Xaa 20 is Arg or Leu
  • Xaa 19 and Xaa 21 are independently Lys, Ala, or Arg;
  • Xaa 22-31 is selected from (SEQ ID NOS : 26 , 27 , 28 , 29 , or 30); Xaa 32 is His ,
  • Xaa 33 is absent, or is Pro, Thr, Glu, or Ala;
  • Xaa 34 is absent, or is Pro, Arg, Met, Ala, hSer, hSer lactone, Tyr, Leu, or 1 , 4 -diaminobutyryl lactam;
  • Xaa 35 is absent or is Pro, Glu, Ser, Ala, or Gly;
  • Xaa 36 is absent or is Ala, Arg, or Ile;
  • Xaa 37 is absent or is Arg, Trp, or 3- (-2-naphthyl) -L-alanine;
  • Xaa 38 is absent or is Ala or hSer or Xaa 38j)2 is Thr Arg Ser Ala Trp;
  • Term is OR or NR 2 where each R is independently H, (C,-C 4 )alkyl or phenyl (C 1 -C 4 )alkyl; and the pharmaceutically acceptable salts thereof.
  • this invention provides analogs of PTH,
  • amino acid residues (22-31) form an amphipathic ⁇ -helix, the sequence of said residues (22-31) selected from:
  • Xaa is Glu or Arg (SEQ ID NO: 26);
  • Xaa 29 is Glu, Lys, or Lys (COCH-PEGX) and PEGX is a poly- (ethylene glycol methyl ether) radical of molecular weight 100 to 10,000 (SEQ ID NO:27); c) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO:28);
  • compositions for the prevention or treatment of conditions characterized by decreases in bone mass comprising an effective bone mass increasing amount of a polypeptide analog of parathyroid hormone (PTH) , parathyroid hormone related peptide (PTHrp) , and of the physiologically active truncated homologs and analogs of PTH and
  • amino acid residues (22-31) form an amphipathic ⁇ -helix
  • said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence: Haa (Laa Laa Haa Haa), Laa. in admixture with a pharmaceutically acceptable carrier.
  • processes for preparing pharmaceutical compositions which comprise mixing the above described compounds with a pharmaceutically acceptable carrier.
  • this invention provides methods for treating mammalian conditions characterized by decreases in bone mass which methods comprise administering to a mammal in need thereof an effective bone mass increasing amount of a polypeptide analog of PTH, PTHrp, or of a physiologically active truncated homolog or analog of PTH or PTHrp, or a salt thereof, in which amino acid residues (22-31) form an amphipathic ⁇ -helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:
  • this invention provides methods for treating mammalian conditions characterized by decreases in bone mass which methods comprise administering to a mammal in need thereof an effective bone mass increasing amount of a polypeptide analog of PTH, PTHrp, or of a
  • amino acid residues (22-31) form an amphipathic ⁇ -helix, the sequence of said residues (22-31) selected from: (SEQ ID NOS: 26, 27, 28, 29, and 30).
  • This invention also includes processes for the solid phase synthesis of polypeptide analogs of PTH, PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic ⁇ -helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:
  • Haa (Laa Laa Haa Haa) 2 Laa which processes comprise sequentially coupling protected amino acids on a suitable resin support, removing the side chain and W-protecting groups, and cleaving the polypeptide from the resin.
  • This invention also encompasses processes for the solid phase synthesis of polypeptide analogs of PTH, pTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic ⁇ -helix, the sequence of said residues (22-31) selected from: (SEQ ID NOS: 26, 27, 28, 29, and 30); which processes comprise sequentially coupling protected amino acids on a suitable resin support, removing the side chain and N ⁇ -protecting groups, and cleaving the polypeptide from the resin.
  • amino acid residues (22-31) form an amphipathic ⁇ -helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:
  • the invention also encompasses DNA sequences, vectors, and plasmids for the recombinant synthesis of such polypeptide analogs.
  • the invention provides DNA sequences, vectors, and plasmids for the recombinant synthesis of polypeptide analogs of PTH, PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic ⁇ -helix, the sequence of said residues (22-31) selected from: (SEQ ID NOS: 26, 27, 28, 29, and 30). BRIEF DESCRIPTION OF THE DRAWINGS
  • Figure 1 presents the DNA sequence and enzyme restriction sites of a synthetic gene coding for a PTHrp (1-34) analog of this invention (hPTH PCR Amplification).
  • Figure 2 outlines the preparation of a plasmid incorporating a
  • Figure 3 outlines the preparation of a plasmid incorporating two copies of a PTHrp(1-34) analog gene (Trp LE 18 hPTHrp (1-34) 2 Construction).
  • Figure 4 outlines the preparation of a plasmid incorporating four copies of a PTHrp(1-34) analog gene (Trp LE 18 hPTHrp (1-34) 4 Construct).
  • Valine Val V The abbreviations represent L-amino acids unless otherwise designated as D- or D,L-. Certain amino acids, both natural and non-natural, are achiral, e.g. glycine. All peptide sequences are presented with the N-terminal amino acid on the left and the C-terminal amino acid on the right.
  • Hydrophilic amino acid refers to an amino acid having at least one hydrophilic functional group in addition to those required for peptide bond formation, such as arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, and their homologs.
  • Lipophilic amino acid (Laa) refers to an uncharged, aliphatic or aromatic amino acid, such as isoleucine, leucine, methionine,
  • alanine is classified as
  • amphiphilic i.e., capable of acting as either hydrophilic or lipophilic.
  • Physiologically active truncated homolog or analog of PTH or PTHrp refers to a polypeptide having a sequence comprising less than the full complement of amino acids found in PTH or PTHrp which, however, elicits a similar physiological response.
  • the truncated PTH or PTHrp need not be fully homologous with PTH or PTHrp to elicit a similar physiological response.
  • PTH (1-34) and PTHrp (1-34) are preferred, but not exclusive, representatives of this group.
  • Amphipathic ⁇ -helix refers to the secondary structure exhibited by certain polypeptides in which the amino acids assume an ⁇ -helical
  • ⁇ H [ ( ⁇ H N sin ⁇ (N-1) ) 2 + ( ⁇ H N cos ⁇ (N-1) ) 2 ] 1 ⁇ 2 ,
  • the hydrophobic moment may be expressed as the mean hydrophobic moment per residue by dividing ⁇ H by N to obtain ⁇ H >.
  • a value of ⁇ H > at 100° ⁇ 20° of about 0.20 or greater is suggestive of amphipathic helix formation.
  • the ⁇ H > values at 100° for hPTHrp (22-31) and hPTH (22-31) are 0.19 and 0.37, respectively.
  • amphipathic index as a predictor of amphipathicity. They concluded that approximately half of all known ⁇ -helices are amphipathic, and that the dominant frequency is 97.5° rather than 100°, with the number of residues per turn being closer to 3.7 than 3.6. While such refinements are scientifically interesting, the basic approach of Eisenberg, et al. is sufficient to classify a given sequence as amphipathic, particularly when one is designing a sequence ab initio to form an amphipathic
  • a substitute amphipathic ⁇ -helical amino acid sequence may lack homology with the sequence of a given segment of a naturally occurring polypeptide but elicits a similar secondary structure, i. e. an ⁇ -helix having opposing polar and nonpolar faces, in the physiological environment.
  • Replacement of the naturally occurring amino acid sequence with an alternative sequence may beneficially affect the physiological activity, stability, or other properties of the altered parent polypeptide. Guidance as to the design and selection of such sequences is provided in J. L.
  • Haa's are selected from the group of hydrophilic amino acids and the Laa's are selected from the group of lipophilic amino acids, as defined above.
  • residues 1, 4, 5, 8, and 9 are distributed along one face (A) of the helix within about a 140° arc of each other, while residues 2, 3, 6, 7, and 10 occupy an opposing 140° arc on the other face (B) of the helix.
  • all the residues on one face are of the same polarity while all those on the other face are of the opposite polarity, i.e., if face A is all hydrophilic, face B is all lipophilic and vice versa.
  • face A is all hydrophilic
  • face B is all lipophilic and vice versa.
  • Laa (Haa Haa Laa Laa) 2 Haa will also meet the residue distribution criteria and is an equivalent descriptor of the helices of this invention.
  • Alanine may be substituted for either hydrophilic or lipophilic amino acids, since Ala can reside readily on either face of an amphipathic ⁇ -helix, although Ala 10 does not form an amphipathic ⁇ -helix.
  • proline, cysteine, and tyrosine are not used; however, their presence and other random errors in the sequence may be tolerated, e.g. a hydrophilic residue on the lipophilic face, as long as the remaining amino acids in the segment substantially conform to the hydrophilic face - lipophilic face division.
  • sufficiently amphipathic to be a sequence of this invention is to calculate the mean hydrophobic moment, as defined above. If the peak mean moment per residue at 100° ⁇ 20° exceeds about 0 .20 , then the sequence will form an amphipathic helix and is a sequence of this invention.
  • the mean peak hydrophobic moment occurs at 92° and has a value of 0.48.
  • this invention provides analogs of PTH, PTHrp, and the physiologically active truncated analogs and homologs of PTH and PTHrp, or salts thereof, in which amino acid residues (22-31) form an amphipathic ⁇ -helix, the sequence of said residues (22-31) selected from:
  • Xaa 1 and Xaa 4 are independently Glu, Glu(0CH 3 ), His, or Phe;
  • Xaa 2 is Leu or Phe;
  • Xaa 5 is Lys or His;
  • Xaa 7 and Xaa 10 are independently Leu or Ile;
  • Xaa 8 is Ala, Arg, or Glu; and
  • Xaa 9 is Lys or Glu (SEQ ID NO:26);
  • Xaa 1 and Xaa 4 are independently Glu, Glu(OCH 3 ), His, or Phe; Xaa 2 is Leu or Phe; Xaa 8 is Glu, Lys, or Lys (COCH 2 PEGX) and PEGX is a poly- (ethylene glycol methyl ether) radical of molecular
  • this invention provides analogs of PTH, PTHrp, and the physiologically active truncated analogs and homologs of PTH and PTHrp, or salts thereof, of the formula:
  • Xaa 1 is absent or is Ala
  • Xaa 2 is absent or is Val ;
  • Xaa 3 is absent or is Ser ;
  • Xaa 4 is absent or is Glu or Glu (OCH 3 );
  • Xaa 5 is absent or is His or Ala
  • Xaa 6 is absent or is Gln;
  • Xaa 7 is absent or is Leu;
  • Xaa 10 and Xaa 17 are independently Asp or Asp (OCH 3 );
  • Xaa 11 is Lys , Arg, or Leu;
  • Xaa 13 is Lys , Arg, Tyr, Cys , Leu, Cys (CH 2 CONH (CH 2 ) 2 NH (biotinyl) ) , Lys (7 -dimethylamino-2 -oxo-2H- 1 -benxopyran-4 -acetyl) , or Lys (dihydrocinnamoyl);
  • Xaa 20 is Arg or Leu;
  • Xaa 19 and Xaa 21 are independently Lys , Ala, or Arg;
  • Xaa 22"31 is selected from (SEQ ID NOS : 26 , 27 , 28 , 29 , or 30); Xaa 32 is His ,
  • Xaa 33 is absent, or is Pro, Thr, Glu, or Ala;
  • Xaa 34 is absent, or is Pro, Arg, Met, Ala, hSer, hSer lactone, Tyr, Leu, or
  • Xaa 35 is absent or is Pro, Glu, Ser, Ala, or Gly;
  • Xaa 36 is absent or is Ala, Arg, or Ile;
  • Xaa 37 is absent or is Arg, Trp, or 3- (-2-naphthyl) -L-alanine;
  • Xaa 38 is absent or is Ala or hSer or Xaa 3iM2 is Thr Arg Ser Ala Trp;
  • Term is OR or NR- where each R is independently H, (C,-C 4 )alkyl or phenyl (C 1 -C 4 )alkyl; and the pharmaceutically acceptable salts thereof.
  • this invention includes polypeptide analogs of the physiologically active truncated homolog hPTHrp (1-34) , as shown in Formula (I) :
  • Xaa 5 is His or Ala
  • Xaa 22-31 is selected from:
  • Xaa is Glu or Arg (SEQ ID NO:26);
  • Xaa is Glu, Lys, or Lys (COCHjPEGX) and PEGX is a
  • Xaa 32 is His or Lys
  • Xaa 33 is Thr, Glu, or Ala
  • Xaa 34 is Ala, hSer, Tyr, or Leu;
  • a more specific aspect of the invention includes
  • a still more specific aspect of the invention includes those Formula (I) polypeptides wherein Xaa 22-31 is (SEQ ID NO: 26); Xaa 11 and Xaa 13 are both Lys; and Xaa 19 and Xaa 21 are both Arg.
  • polypeptides include, but are not limited to:
  • Another aspect of this invention includes those polypeptides of Formula (I) wherein Xaa 22-31 is (SEQ ID NO:26); Xaa 11 and Xaa 13 are both Lys; and one of Xaa 19 and Xaa 21 is Arg and the other is Ala.
  • Representative poly-peptides of this subgenus include, but are not limited to:
  • this invention includes those polypeptides of
  • Xaa 22-31 is (SEQ ID NO:26); one of Xaa 11 and Xaa 13 is Leu and the other is Lys; and Xaa 19 and Xaa 21 are both Arg.
  • Representative polypeptides of this subgenus include , but are not limited to :
  • this invention includes those polypeptides of Formula (I) wherein Xaa 22-31 is (SEQ ID N0:27) , for which ⁇ H > at 100° exceeds 0.50.
  • a further aspect of this invention includes those Formula (I) polypeptides wherein Xaa 22-31 is (SEQ ID NO:27); Xaa 11 and Xaa 13 are both Lys or both Arg; and Xaa 19 and Xaa 21 are both Arg.
  • Representative polypeptides of this subgenus include, but are not limited to:
  • this invention includes polypeptides of Formula (I) wherein Xaa 22-31 is (SEQ ID NO:28) , for which ⁇ H > at 100° is about 0.25.
  • Representative polypeptides of this subgenus include, but are not limited to:
  • this invention includes polypeptides of Formula (I) wherein Xaa 22-31 is (SEQ ID NO:29) , for which ⁇ H > at 100° is about 0.28.
  • polypeptides of this subgenus include, but are not limited to:
  • this invention includes polypeptides of Formula (I) wherein Xaa 22-31 is (SEQ ID NO:30) , for which ⁇ H > at 100° is about 0.29.
  • Representative polypeptides of this subgenus include, but are not limited to:
  • Still another aspect of this invention includes polypeptide analogs of the physiologically active truncated homolog bPTH(1-34), as shown in
  • Xaa 1 is Ser or Ala
  • Xaa 7 is Leu or Phe ;
  • Xaa 8 is Met or Nle ;
  • Xaa 16 is Asn or Ser
  • Xaa 18 is Leu, Met, or Nle ;
  • Xaa 19 is Glu or Arg
  • Xaa 21 is Val or Arg
  • Xaa 22-31 is selected from (SEQ ID NO : 26 , 27 , 28, 29 , and 30);
  • Xaa 34 is Phe or Tyr
  • Term is OH or NR 2 , where each R is H or (C 1 -C 4 ) alkyl ;
  • polypeptides include, but are not limited to :
  • polypeptides include, but are not limited to:
  • polypeptides of the instant invention may be synthesized by methods such as those set forth in
  • these methods involve the sequential addition of protected amino acids to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid and any reactive side chain group are protected. This protected amino acid is then either attached to an inert solid support, or utilized in solution, and the next amino acid in the sequence, also suitably protected, is added under conditions amenable to formation of the amide linkage . After all the desired amino acids have been linked in the proper sequence, protecting groups and any solid support are removed to afford the crude polypeptide. The polypeptide is desalted and purified, preferably chromatographically, to yield the final product.
  • a preferred method of preparing the analogs of the physiologically active truncated polypeptides, having fewer than about forty amino acids involves solid phase peptide synthesis.
  • this method the ⁇ -amino (N ⁇ ) functions and any reactive side chains are protected by acid- or
  • the protecting group should be stable to the conditions of peptide linkage formation, while being readily removable without affecting the extant polypeptide chain.
  • protecting groups include, but are not limited to t-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), o-chlorobenzyloxycarbonyl,
  • Suitable side chain protecting groups include, but are not limited to: acetyl, benzyl (Bzl), benzyloxymethyl (Bom), o-bromobenzyloxycarbonyl, t-butyl,
  • Suitable resin supports are those materials which are inert to the reagents and reaction conditions of the stepwise condensation and deprotection reactions, as well as being insoluble in the media used. Examples of commercially available resins include
  • styrene/divinylbenzene resins modified with a reactive group e.g., chloromethylated co-poly-(styrene-divinylbenzene), hydroxymethylated co-poly-(styrene-divinylbenzene), and the like.
  • a reactive group e.g., chloromethylated co-poly-(styrene-divinylbenzene), hydroxymethylated co-poly-(styrene-divinylbenzene), and the like.
  • Benzylated, hydroxymethylated phenylacetamidomethyl (PAM) resin is preferred.
  • C-terminus of the compound is an amide
  • a preferred resin is
  • Attachment to the PAM resin may be accomplished by reaction of the
  • ⁇ T-protected amino acid preferably the Boc-amino acid, as its ammonium, cesium, triethylammonium, 1,5-diazabicyclo-[5.4.0]undec-5-ene,
  • DMF N,N-dimethylformamide
  • the N ⁇ -Boc-amino acid may be attached to the benzhydrylamine resin by means of, for example, an N,N'-diisopropylcarbodiimide
  • DIC /1-hydroxybenzotriazole (HOBt) mediated coupling for from about 2 to about 24 hours, preferably about 2 hours at a temperature of between about 10° and 50°C, preferably 25°C in a solvent such as dichloro-methane or dimethylformamide, preferably dichloromethane.
  • a solvent such as dichloro-methane or dimethylformamide, preferably dichloromethane.
  • each protected amino acid is preferably introduced in approximately 1.5 to 2.5 fold molar excess and the coupling carried out in an inert, nonaqueous, polar solvent such as dichloromethane, DMF, or mixtures thereof, preferably in dichloromethane at ambient temperature.
  • Representative coupling agents are N,N' -dicyclohexylcarbodiimide (DCC) , N,N'-diisopropyl-carbodiimide (DIC) or other carbodiimide, either alone or in the presence of
  • cleavage may be effected by means of aminolysis with an alkylamine or fluoroalkylamine for peptides with an alkylamide C-terminus, or by aminolysis with, for example, ammonia/methanol or ammonia/ethanol for peptides with an unsubstituted amide C-terminus, at a temperature between about -10° and 50°C, preferably about 25°C, for between about 12 and 24 hours, preferably about 18 hours.
  • Peptides with a hydroxy C-terminus may be cleaved by HF or other strongly acidic deprotection regimen or by saponification.
  • the peptide may be removed from the resin by transesterification, e.g., with methanol, followed by aminolysis or saponification.
  • the protected peptide may be purified by silica gel chromatography.
  • the side chain protecting groups may be removed from the peptide by treating the aminolysis product with, for example, anhydrous liquid hydrogen fluoride in the presence of anisole or other carbonium ion scavenger, treatment with hydrogen fluoride/pyridine complex, treatment with tris(trifluoroacetyl) boron and trifluoroacetic acid, by reduction with hydrogen and palladium on carbon or polyvinylpyrrolidone, or by reduction with sodium in liquid ammonia, preferably with liquid hydrogen fluoride and anisole at a temperature between about -10° and +10°C, preferably at about 0°C, for between about 15 minutes and 2 hours, preferably about 1.5 hours.
  • anhydrous liquid hydrogen fluoride in the presence of anisole or other carbonium ion scavenger
  • treatment with hydrogen fluoride/pyridine complex treatment with tris(trifluoroacetyl) boron and trifluoroacetic acid
  • hydrogen and palladium on carbon or polyvinylpyrrolidone
  • the resin cleavage and deprotection steps may be combined in a single step utilizing liquid hydrogen fluoride and anisole as described above.
  • the solution may be desalted (e.g. with BioRad AG-3 ® anion exchange resin) and the peptide purified by a sequence of chromatographic steps employing any or all of the following types: ion exchange on a weakly basic resin in the acetate form; hydrophobic adsorption chromatography on underivatized co-poly (styrene-divinylbenzene), e.g.. Amberlite ® XAD; silica gel adsorption chromatography; ion exchange chromatography on
  • HPLC octyl- or octadecylsilylsilica
  • Another aspect of the present invention relates to processes for preparing polypeptides and pharmaceutically acceptable salts thereof which processes comprise sequentially condensing protected amino acids on a suitable resin support, removing the protecting groups and resin support, and purifying the product, to afford analogs of the physiologically active truncated homologs and analogs of PTH and PTHrp, preferably of PTH(1-34) and PTHrp(1-34), in which the amino acids at positions (22-31) form an amphipathic ⁇ -helical peptide sequence, as defined above.
  • the polypeptides of this invention may be prepared by cloning and expression of a gene encoding for the desired polypeptide.
  • a plasmid containing the desired DNA sequence is prepared and inserted into an appropriate host microorganism, typically a bacteria, such as E. coli, or a yeast, such as Saccharomyces cerevisiae, inducing the host microorganism to produce multiple copies of the plasmid, and so of the cDNA encoding for the polypeptide analogs of this invention.
  • PTH or PTHrp analog is designed with convenient restriction enzyme cleavage sites to facilitate subsequent alterations.
  • Polymerase chain reaction (PCR) as taught by Mullis in U. S. Patent Nos. 4,683,195 and 4,683,202, may be used to amplify the sequence.
  • the amplified synthetic gene may be isolated and ligated to a suitable plasmid, such as a Trp LE plasmid, into which four copies of the gene may be inserted in tandem.
  • a suitable plasmid such as a Trp LE plasmid
  • Trp LE plasmids Preparation of Trp LE plasmids is described in U.S. Patent No. 4,738,921 and European Patent Publication No. 0212532.
  • Trp LE plasmids generally produce 8-10 times more protein than Trp E plasmids.
  • the multi-copy gene may then be expressed in an
  • E. coli or S. cerevisiae.
  • Trp LE 18 Prot (Ile 3 , Pro 5 ) containing the following elements: a pBR322 fragment (EcoRI-BamHI) containing the ampicillin resistant gene and the plasmid origin of replication; an EcoRI-SacII fragment containing the trp promoter and the trpE gene; an HIV protease (Ile 3 , Pro 5 ) gene fragment (SacII-HindIII); a bGRF gene fragment (HindIII-BamHI); and a transcription terminator from E. coli rpoc gene.
  • the HIV protease and bGRF gene fragments are not critical and may be replaced with other coding sequences, if desired.
  • the expressed multimeric fusion proteins accumulate intracellularly into stable inclusion bodies and may be separated by centrifugation from the rest of the cellular protein.
  • the isolated fusion protein is converted to the monomeric PTH or PTHrp analog and may be purified by cation exchange and/or reverse phase HPLC.
  • polypeptides of this invention are useful for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass.
  • the compounds of this invention are indicated for the prophylaxis and therapeutic treatment of osteoporosis and osteopenia in humans.
  • the polypeptides of this invention, or salts thereof are administered in amounts between about 0.002 and 1 ⁇ g/kg body weight per day, preferably from about 0.04 to about 0.2 ⁇ g/kg body weight per day.
  • the daily dose of active ingredient is from about 0.1 to about 50 ⁇ gs, preferably from about 2.0 to about 10 ⁇ gs. In other mammals, such as horses, dogs, and cattle, higher doses may be required.
  • This dosage may be delivered in a conventional pharmaceutical composition by a single administration, by multiple applications, or via controlled release, as needed to achieve the most effective results, preferably one or more times daily by injection.
  • the selection of the exact dose and composition and the most appropriate delivery regimen will be influenced by, inter alia, the pharmacological properties of the selected polypeptide, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient.
  • Representative delivery regimens include oral, parenteral (including subcutaneous, intramuscular and intravenous), rectal, buccal (including sublingual), pulmonary, transdermal, and intranasal.
  • salts retain the desired biological activity of the parent polypeptide without toxic side effects.
  • examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acids, naphthalene disulfonic acids,
  • polygalacturonic acid and the like (b) base addition salts formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, and the like; or with an organic cation formed from N,N'-dibenzylethylenediamine or ethylenediamine; or (c) combinations of (a) and (b), e.g., a zinc tannate salt and the like.
  • polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, and the like
  • organic cation formed from N,N'-dibenzylethylenediamine or ethylenediamine or combinations of (a) and (b), e.g., a zinc tannate salt and the like.
  • a further aspect of the present invention relates to pharmaceutical compositions comprising as an active ingredient a polypeptide of the present invention, or pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable, non-toxic carrier.
  • compositions may be prepared for parenteral
  • compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington 's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA., (1985).
  • Formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like.
  • the formulation can be enhanced by the addition of bile salts or acylcarnitines.
  • Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use in the form of nasal drops or metered spray.
  • excipients include sugars, calcium stearate, magnesium stearate,
  • pregelatinated starch and the like.
  • the absorption across the nasal mucous membrane may be enhanced by surfactant acids, such as for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, deoxycholic acid, chenodeoxycholic acid, dehydrocholic acid,
  • surfactant acids such as for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, deoxycholic acid, chenodeoxycholic acid, dehydrocholic acid,
  • glycodeoxycholic acid cyclodextrins and the like in an amount in the range between about 0.2 and 15 weight percent, preferably between about 0.5 and 4 weight percent, most preferably about 2 weight percent.
  • Delivery of the compounds of the present invention to the subject over prolonged periods of time, for example, for periods of one week to one year, may be accomplished by a single administration of a controlled release system containing sufficient active ingredient for the desired release period.
  • a controlled release system containing sufficient active ingredient for the desired release period.
  • Various controlled release systems such as monolithic or reservoir-type microcapsules, depot implants, osmotic pumps, vesicles, micelles, liposomes, transdermal patches, iontophoretic devices and alternative injectable dosage forms may be utilized for this purpose.
  • Localization at the site to which delivery of the active ingredient is desired is an additional feature of some controlled release devices, which may prove beneficial in the treatment of certain disorders.
  • controlled release formulation contains the polypeptide or its salt dispersed or encapsulated in a slowly degrading, non-toxic, non-antigenic polymer such as copoly (lactic/glycolic) acid, as described in the pioneering work of Kent, Lewis, Sanders, and Tice, U.S. 4,675,189.
  • the compounds or, preferably, their relatively insoluble salts may also be formulated in cholesterol or other lipid matrix pellets, or silastomer matrix implants. Additional slow release, depot implant or injectable formulations will be apparent to the skilled artisan. See, for example,
  • the protected amino acids were obtained from Applied Biosystems Inc. (Foster City, CA) .
  • EXAMPLE I Compound 1 (SEQ ID NO: 7) was prepared on 0.5 mmol scale by the solid phase method on 4-methylbenzhydrylamine resin, using an automated Applied Biosystems Model 430A peptide synthesizer. The ⁇ -amino groups were protected with t-butoxycarbonyl (Boc) . The side chain protecting groups were: benzyl (Bzl) for Asp, Glu, and Ser; tosyl (Tos) for Arg;
  • the completed peptide was cleaved from the resin with simultaneous deprotection of the side chain protecting groups using anhydrous HF (25 mL) in the presence of anisole (2.5 mL) at -10°C for 30 minutes and at 0°C for 60 minutes. After evaporation of the HF in vacuo, the residue was washed with anhydrous ether, and the crude peptide extracted with 10% acetic acid.
  • Lyophilization of the 10% acetic acid extract gave 900 mgs of crude product.
  • the peptide was purified by medium pressure ODS reversed phase column chromatography using a gradient of 22-45% CH 3 CN in 0.1% TFA.
  • the product eluted in three fractions, which were concentrated and lyophilized to give 130 mgs of white solid of >98% purity.
  • AAA Asp, 1.9(2); Glu, 5.6(6); Ser, 1.6(2); His, 2.7(3); Gly, 1.0(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 2.8(3); Val, 1.0(1); Ile, 0.9(1); Leu, 7.3(8); Lys, 4.0(4) .
  • AAA Asp, 2.1(2); Glu, 5.9(6); Ser, 1.7(2); His, 2.9(3); Gly 1.1(1); Thr,
  • AAA Asp, 2.1(2); Gly, 6.1(6); Ser, 1.8(2); His, 3.1(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 5.0(5); Val, 1.0(1); Ile, 0.9(1); Leu, 7.7(8); Lys, 1.9(2) .
  • AAA Asp, 2.1(2); Glu, 6.1(6); Ser, 1.8(2); His, 3.2(3); Gly, 1.2(1); Thr,
  • AAA Asp, 2.0(2); Glu, 4.8(5); Ser, 1.8(2); His, 3.2(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 6.7(7); Val, 1.0(1); Ile, 1.0(1); Lys,
  • AAA Asp, 2.0(2); Glu, 4.8(5); Ser, 1.8(2); His, 2.7(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 2.0(2); Arg, 3.9(4); Val, 1.0(1); Ile, 1.0(1); Leu, 7.9(8); Lys, 4.0(4) .
  • AAA Asp, 2.0(2); Glu, 5.9(6); Ser, 1.7(2); His, 2.9(3); Gly, 2.3(2); Thr, 1.0(1); Ala, 1.9(2); Arg, 5.0(5); Val, 1.2(1); Ile, 1.0(1); Leu, 7.8(8); Lys, 4.3(4). .ompound 10
  • AAA Asp, 2.0(2); Glu, 6.0(6); Ser, 1.8(2); His, 2.0(2); Gly, 1.2(1); Ala, 3.0(3); Arg, 2.8(3); Val, 1.1(1); Ile, 1.0(1); Leu, 9.9(10); Lys, 3.0(3) .
  • AAA Asp, 2.2(2); Glu, 7.7(7); Ser, 1.7(2); His, 2.0(2); Gly, 1.0(1); Ala,
  • AAA Asp, 2.1(2); Glu, 6.5(6); Ser, 2.7(3); His, 3.1(3); Gly, 1.1(1); Ala, 1.0(1); Arg, 1.0(1); Tyr, 0.8(1); Val, 2.0(2); Phe, 1.0(1); Ile,
  • AAA Asp, 2.1(2); Glu, 5.5(5); Ser, 2.6(3); His, 3.1(3); Ala, 1.0(1); Gly, 1.1(1); Arg, 3.2(3); Tyr, 1.0(1); Val, 1.0(1); Phe, 1.0(1); Ile, 1.0(1); Leu, 9.0(9); Lys, 3.0(3) .
  • AAA Asp, 2.1(2); Glu, 4.9(5); Ser, 1.7(2); His, 2.6(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 7.6(7); Arg, 2.8(3); Val, 1.2(1); Ile, 1.0(1); Leu, 6.6(6) ; Lys, 1.9(2) .
  • AAA Asp, 2.1(2); Glu, 6.1(6); Ser, 1.7(2); His, 3.1(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 3.0(3); Arg, 2.1(2); Val, 1.1(1); Ile, 1.0(1); Leu, 8.0(8) ; Lys, 4.4(4) .
  • AAA Asp, 2.1(2); Glu, 6.0(6); Ser, 1.8(2); His, 3.1(3); Gly, 1.1(1); Thr,
  • AAA Asp, 2.1(2); Glu, 2.9(3); Ser, 6.8(7); His, 3.1(3); Gly, 1.2(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.0(3); Val, 1.0(1); Ile, 1.0(1); Leu, 8.2(8) ; Lys, 2.0(2) .
  • AAA Asp, 2.9(3) , Glu, 3.5(4); Ser, 1.4(2); His, 2.6(3); Gly, 0.9(1); Thr,
  • AAA Asx, 2.1(2); Glx, 5.0(5); Ser, 2.7(3); His, 3.0(3); Gly, 1.0(1); Ala,
  • AAA Asx, 2.0(2); Glx, 4.9(5); Ser, 2.6(3); His, 2.8(3); Gly, 1.0(1); Ala, 1.0(1); Arg, 3.0(3); Val, 1.0(1); Phe, 1.0(1); Ile, 0.9(1); Leu, 8.8(9) ; Lys, 3.4(3) ;
  • AAA Asx, 2.1(2); Glx, 4.9(5); Ser, 2.7(3); His, 2.8(3); Gly, 1.0(1);
  • AAA Asx, 2.1(2); Glx, 6.5(6); Ser, 1.8(2); His, 3.1(3); Gly, 1.1(1); Thr,
  • AAA Asx, 2.2(2); Glx, 6.2(6); Ser, 1.8(2); His, 3.2(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.1(2); Arg, 5.2(5); Val, 1.1(1); Ile, 1.1(1); Leu, 8.4(8) ; Lys, 2.2(2) .
  • AAA Asx, 2.1(2); Glx, 6.2(6); Ser, 1.8(2); His, 2.9(3); Gly, 1.1(1); Thr,
  • AAA Asx, 2.1(2); Glx, 5.9(6); Ser, 1.6(2); His, 2.7(3); Gly, 2.2(2); Thr, 1.0(1); Ala, 1.8(2); Arg, 7.3(7); Val, 0.8(1); Ile, 1.0(1); Leu, 8.1(8) ; Lys, 2.1(2) .
  • AAA Asx, 2.2(2); Glx, 6.1(6); Ser, 1.7(2); His, 3.0(3); Gly, 1.9(2);
  • AAA Asx, 2.0(2); Glx, 5.6(6); Ser, 1.7(2); His, 3.1(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 0.9(1); Arg, 3.0(3); Tyr, 0.9(1); Val, 1.0(1); Ile,
  • AAA Asx, 2.0(2); Glx, 5.5(6); Ser, 1.8(2); His, 3.4(3); Gly, 1.1(1); Thr,
  • AAA Asx+Cys, 3.0(2+1); Glx, 5.6(6); Ser, 1.7(2); His, 3.0(3); Gly,
  • AAA Asx, 2.2(2); Glx, 6.1(6); Ser, 1.8(2); His, 3.8(3); Gly, 1.0(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.1(3); Val, 1.1(1); Ile, 0.9(1); Leu, 8.3(3); Lys, 3.3(3).
  • AAA Asx, 1.9(2); Glx, 6.3(6); Ser, 1.7(2); His, 3.2(3); Gly, 1.0(1); Thr, 1.1(1); Ala, 2.0(2); Arg, 3.2(3); Val, 1.1(1); Ile, 0.9(1); Leu, 8.2(8); Lys, 4.5(4).
  • AAA Asx, 2.0(2); Glx, 5.7(6); Ser, 1.8(2); His, 3.0(3); Gly, 2.2(2); Thr, 0.9(1); Ala, 1.9(2); Arg, 2.8(3); Val, 1.2(1); Ile, 0.9(1); Leu,
  • AAA Asx, 2.1(2); Glx, 6.3(6); Ser, 1.8(2); His, 3.3(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.1(3); Val, 1.1(1); Ile, 0.9(1); Leu, 8.0(8); Lys, 4.2(4) .
  • AAA Asx, 2.1(2); Glx, 6.2(6); Ser, 1.4(2); His, 3.0(3); Gly, 1.1(1); Thr, 1.1(1); Ala, 1.7(2); Arg, 3.2(3); Val, 0.6(1); Ile, 0.9(1); Leu, 8.0(8); Lys, 4.1(4).
  • AAA Asx, 2.1(2); Glx, 5.9(6); Ser, 2.0(2); His, 3.1(3); Gly, 0.8(1);
  • hSer 0.8(1); Thr, 1.0(1); Ala, 1.0(1); Arg, 3.0(3); Val, 1.3(1); Ile, 1.0(1); Leu, 8.1(8); Lys, 3.8(4).
  • AAA Asx, 2.0(2); Glx, 5.6(6); Ser, 1.7(2); His, 2.9(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 2.9(3); Val, 1.2(1); Ile, 1.0(1); Leu, 7.7(8); Lys, 4.3(4) .
  • AAA Asx, 2.0(2); Glx, 5.5(6); Ser, 1.8(2); His, 2.9(3); Gly, 1.0(1); Thr, 1.0(1); Ala, 0.9(1); Arg, 2.9(3); Val, 1.2(1); Ile, 0.9(1); Leu,
  • AAA Asx, 2.0(2); Glx, 5.6(6); Ser, 1.9(2); His, 2.9(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 0.9(1); Arg, 2.8(3); Val, 1.2(1); Ile, 1.1(1); Leu,
  • AAA Asx, 2.0(2); Glx, 5.7(6); Ser, 1.8(2); His, 3.0(3); Gly, 1.1(1); Ala,
  • AAA Asx, 2.2(2); Glx, 5.9(6); Ser, 1.9(2); His, 2.1(2); Gly, 1.1(1); Ala, 1.0(1); Arg, 3.0(3); Val, 1.1(1); Ile, 1.0(1); Leu, 7.9(8); Lys, 4.3(4); Pro, 0.9(1).
  • AAA Asx, 2.0(2); Glx, 5.8(6); Ser, 2.8(3); His, 2.8(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 3.7(4); Ile, 0.9(1); Leu, 7.5(8); Lys,
  • AAA Asx, 2.2(2); Glx, 6.0(6); Ser, 2.7(3); His, 3.0(3); Gly, 2.2(2); Thr,
  • AAA Asx, 1.9(2); Glx, 5.6(6); Ser, 2.6(3); His, 3.3(3); Gly, 2.1(2); Thr,
  • AAA Asx, 2.1(2) , Glx, 6.3(6); Ser, 2.8(3); His, 3.2(3); Gly, 2.1(2) , Thr, 2.0(2); Ala, 3.2(3); Arg, 9.9(9); Val, 1.0(1) , Ile, 0.9(1); Leu, 8.6(8); Lys, 1.1(1); Trp, 1.1(1) .
  • Compound 47
  • AAA Asx, 3.0(3); Glx, 2.9(3); Ser, 3.7(4); His, 2.8(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 2.0(2); Tyr, 1.0(1); Val, 1.7(2); Phe, 0.9(1); Ile, 0.9(1); Leu+Nle 5.8(2+4); Lys, 3.4(3); Trp, 1.1(1).
  • AAA Asx, 2.3(2); Glx, 6.6(6); Ser, 1.4(2); His, 3.2(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.1(3); Val, 0.9(1); Met, 1.1(1); Ile,
  • AAA Asx, 2.1(2); Glx, 6.3(6); Ser, 1.7(2); His, 3.3(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.1(2); Arg, 2.9(3); Val, 0.9(1); Ile, 0.9(1); Leu, 8.0(8); Lys, 3.8(4) .
  • AAA Asx, 2.2(2); Glx, 5.0(5); Ser, 1.9(2); His, 3.3(3); Gly, 1.0(1); Thr,
  • AAA Asx, 2.2(2); Glx, 4.9(5); Ser, 1.8(2); His, 4.3(4); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.1(3); Val, 1.1(1); Ile, 1.0(1); Leu, 8.1(8); Lys, 3.9(4).
  • AAA Asx, 2.1(2); Glx, 5.9(6); Ser, 1.8(2); His, 4.2(4); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.0(3); Val, 1.1(1); Ile, 0.9(1); Leu,
  • AAA Asx, 2.2(2); Glx, 4.9(5); Ser, 1.8(2); His, 3.1(3); Gly, 1.1(1); Thr,
  • AAA Asx, 2.2(2); Glx, 7.1(7); Ser, 1.7(2); His, 2.8(3); Gly, 1.0(1); Thr, 1.0(1); Ala, 2.1(2); Arg, 3.1(3); Val, 1.1(1); Ile, 1.7(2); Leu, 7.1(7); Lys, 2.7(3).
  • AAA Asx, 2.1(2); Glx, 5.8(6); Ser, 1.7(2); His, 3.1(3); Gly, 0.9(1);
  • AAA Asx, 2.0(2); Glx, 5.9(6); Ser, 1.7(2); His, 2.9(3); Gly, 0.9(1);
  • AAA Asx, 1.9(2); Glx, 5.9(6); Ser, 1.8(2); His, 3.2(3); Gly, 1.1(1); Ala, 2.0(2); Arg, 3.0(3); Thr, 1.0(1); Val, 1.1(1); Ile, 0.9(1); Leu,
  • AAA Asx, 2.0(2); Glx, 5.5(6); Ser, 2.7(3); His, 3.1(3); Gly, 1.0(1); Ala, 1.8(2); Arg, 4.0(4); Thr, 0.9(1); Val, 0.9(1); Ile, 0.9(1); Leu,
  • AAA Asx, 2.1(2); Glx, 5.5(6); Ser, 2.8(3); His, 2.9(3); Gly, 1.0(1); Ala, 2.0(2); Arg, 4.0(4); Thr, 0.9(1); Val, 1.0(1); Ile, 0.9(1); Leu, 7.5(8); Lys, 4.2(4); Nai, 1.1(1).
  • AAA Asx, 2.0(2); Glx, 5.6(6); Ser, 2.7(3); His, 3.2(3); Gly, 1.0(1); Ala, 3.1(3); Arg, 2.8(3); Thr, 1.0(1); Val, 1.1(1); Ile, 0.9(1); Leu,
  • AAA Asx, 2.2(2); Glx, 6.9(7); Ser, 1.7(2); His, 3.2(3); Gly, 1.1(1); Ala,
  • AAA Asx, 2.0(2); Glx, 6.6(7); Ser, 1.9(2); His, 3.4(3); Gly, 1.1(1); Ala, 2.0(2); Arg, 3.8(4); Thr, 1.0(1); Val, 1.1(1); Ile, 1.7(2); Leu,
  • AAA Asx, 2.2(2); Glx, 6.8(7); Ser, 1.8(2); His, 3.3(3); Gly, 1.0(1); Ala, 2.0(2); Arg, 3.0(3); Thr, 1.0(1); Val, 1.0(1); Ile, 1.8(2); Leu,
  • AAA Asx, 2.0(2); Glx, 6.6(7); Ser, 1.9(2); His, 3.3(3); Gly, 1.1(1); Ala, 2.0(2); Arg, 2.9(3); Thr, 1.0(1); Val, 1.1(1); Ile, 1.0(1); Leu, 8.2(8); Lys, 3.8(4) .
  • AAA Asx, 3.1(3); Glx, 4.8(5); Ser, 2.9(3); His, 2.9(3); Gly, 1.1(1); Ala, 1.1(1); Arg, 2.0(2); Val, 2.7(3); Phe, 1.0(1); Ile, 1.0(1); Leu + Nle 5.9 (4 + 2); Lys, 2.8(3) .
  • AAA Asx, 2.0(2); Glx, 5.7(6); Ser, 1.7(2); His, 2.9(3); Gly, 1.0(1); Thr, 0.9(1); Ala, 1.0(1); Arg, 2.8(3); Ile, 0.9(1); Leu, 7.4(8); Lys,
  • AAA Asx, 2.0(2); Glx, 4.1(4); Ser, 0.9(1); His, 2.1(2); Gly, 1.0(1); Thr,
  • AAA Asx, 2.0(2); Glx, 3.9(4); Ser, 0.9(1); His, 1.9(2); Gly, 1.0(1); Thr, 1.0(1); Ala, 1.0(1); Arg, 2.9(3); Ile, 0.9(1); Leu, 6.8(7); Lys, 4.2(4) .
  • AAA Asx, 2.2(2); Glx, 6.2(6); Ser, 2.8(3); His, 3.1(3); Gly, 2.2(2); Thr, 2.2(2); Ala, 2.2(2); Arg, 10.4(10); Ile, 1.0(1); Leu, 8.0(8); Trp, 1.1(1).
  • AAA Asx, 2.1(2); Glx, 4.1(4); Ser, 1.9(2); His, 2.0(2); Gly, 2.1(2); Thr, 2.0(2); Ala, 2.1(2); Arg, 9.7(10); Ile, 0.9(1); Leu, 7.4(8) .
  • Example I This polypeptide was converted to the homoserine lactone as follows.
  • the purified peptide 160 mgs was dissolved in 44% formic acid (4 mL) .
  • This solution was combined with a premixed solution of cyanogen bromide (700 mgs) and phenol (1.6 mgs) in 44% formic acid (4 mL) at 0°C.
  • the solution was stirred at 0°C for 2 hr and at room temperature for 2 hrs.
  • the formation of the product was monitored by HPLC (Vydac ® C-18, 300 A, 4.6 ⁇ 250 mm, flow of 1.2 mL/min, gradient 25-45% acetonitrile in 0.1% TFA over 10 min) .
  • AAA Asp, 2.1(2); Glu, 6.1(6); Ser, 1.8(2); His, 3.0(3); Thi, 1.1(1); Ala, 1.1(1); Arg, 2.7(3); Val, 1.0(1); Ile, 1.0(1); Leu, 8.2(8); Lys,
  • AAA Asp, 2.1(2); Glu, 6.1(6); Ser, 1.6(2); His, 2.8(3); Gly, 0.97(1); hSer, 0.97(1); Thi, 1.0(1); Ala, 1.0(1); Arg, 2.9(3); Val, 1.0(1); Ile, 1.0(1); Leu, 7.6(8); Lys, 3.9(4).
  • BocAVS (Bzl) E (OBz) H (Bom) QLLHD (OBzl) R(Ts) GR (Ts) S (Bzl) IQD (OBz) - LR(Ts)R(Ts)E(OBz)LLE(OBzl)R(Ts)LLK(Fmoc)R(Ts)LH(Bom)T(Bzl)A- O-PAM was synthesized on a 0.35 mmol scale. All N" groups were protected with t-butoxycarbonyl (Boc); side chain protecting groups were as indicated.
  • the peptide resin was treated with 50 mL of 20% piperidine in dimethylformamide (DMF) at room temperature for 30 minutes to remove the fluorenylmethoxy-carbonyl (Fmoc) protecting group on lysine.
  • the resin was washed successively with DMF, MeOH, CH 2 C1 2 and dried to give 1.6 g partially protected peptide.
  • Example I 100 mgs of Compound 19 were obtained.
  • AAA Asp, 2.1(2); Glu, 5.0(5); Ser, 1.6(2); His, 2.9(3); Gly, 0.9(1); Thr, 1.9(2); Arg, 7.1(7); Val, 1.1(1); Ile, 1.0(1); Leu, 8.0(8); Lys, 0.9(1) .
  • AAA Asp, 2.0(2); Glu, 4.8(5); Ser, 1.6(2); His, 2.6(3); Gly, 1.1(1); Thr, 1.1(1); Arg, 7.3(7); Val, 0.8(1); Ile, 0.9(1); Leu, 8.3(8); Lys, 1.1(1); Ala, 1.8(2).
  • a synthetic gene coding for the hPTHrp (1-34) analog Compound 4 (SEQ ID NO: 9) was designed having the nucleotide sequence and enzyme restriction sites shown in Figure 1.
  • the requisite oligodeoxynucleotides were prepared with a DNA synthesizer (Milligen/Biosearch) using the phosphoramidite process of Sinha, et al., Nucleic Acid Research 12, 4539-4557 (1984).
  • oligonucleotides were located with UV, excised from the gel, desalted over Waters cl8 Sep-pak ® cartridges, and lyophilized.
  • PCR polymerase chain reaction
  • PTHPCR2 CCTCGAAGCT TATGCATCAT TATC (SEQ ID NO: 34) , the entire gene was amplified by PCR.
  • the amplified DNA products were purified by gel
  • hPTHrp (1-34) 1 Analog Gene 200 ng of the amplified DNA was isolated and cut by restriction enzymes HinD III and Sac II. As shown in Figure 2, the DNA was ligated to 2 ⁇ g TrpLE 18 Prot (Ile 3 , Pro 5 ) plasmid previously cleaved with Hind III and Sac II.
  • TrpLE 18 hPTHrp (1-34) 1 containing one copy of the hPTHrp (1-34) analog gene was then transformed into competent E. coli HB 101 cells (CLONTECH, Palo Alto, CA) . Transformants were subjected to PCR analysis to verify insertion. Transformed cell colonies were selected and boiled in 200 ⁇ L of water for 5 minutes; 2 ⁇ L were subjected to PCR with two primers flanking the insert. The PCR product was then analyzed on 1% agarose gel to confirm the presence of one copy of the hPTHrp (1-34) gene insert. TrpLE 18 hPTHrp (1-34) 1 construct was then verified by DNA sequencing on an automated DNA sequencer (Applied Biosystems Model 373A, Foster City, CA) using the vendor's Dye Deoxy Terminator Sequencing kit.
  • Nhe I and Xba I restriction sites are located near the beginning and end of the hPTHrp (1-34) analog gene sequence. These two sites, which recognize different sequences, but produce identical single strand cohesive termini, allow the construction of multiple copy
  • hPTHrp (1-34) genes within the Trp LE 18 vector.
  • Trp LE 18 hPTHrp (1-34) 1 The strategy for constructing repeated hPTHrp (1-34) sequences in tandem is outlined in Figure 3.
  • 5 ⁇ g of plasmid Trp LE 18 hPTHrp (1-34) 1 containing a single copy of the gene was cleaved with Bam HI + Nhe I and Xba I + Bam HI. From each digest, about 300 ng of the fragment containing the hPTHrp (1-34) analog gene was isolated. These two fragments were mixed and ligated to form the Trp LE 18 hPTHrp (1-34) 2 plasmid. This plasmid was used to transform competent E. coli HB 101 cells.
  • TrpLE 18 hPTHrp (1-34) 2 containing two copies of the gene was then confirmed by DNA sequencing.
  • the correct fusion of the two hPTHrp (1-34) genes results in the elimination of Nhe I and Xba I sites at the junction. This makes the remaining Xba I and Nhe I sites flanking the tandem genes unique.
  • Trp LE 18 hPTHrp (1-34) 4 containing four copies of the hPTHrp (1-34) gene was constructed, as shown in Figure 4.
  • the sequence of Trp LE 18 hPTHrp (1-34)4 was found to be correct by DNA sequence analysis.
  • the culture was then grown with vigorous shaking to an A 550 of between 0.6 and 0.8, whereupon 2 mL of a 10 mg/mL solution of indole acrylic acid (IAA) was added. Growth was continued with good aeration for about 16 hr to a final A 550 of about 6 (typically, between 4 and 10).
  • the cells were concentrated by centrifugation and resuspended in 500 mL of 50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA buffer solution (Tris buffer).
  • the suspension was sonicated using a Heat Systems-Ultrasonics, Inc. model 220F sonicator (equipped with a 3/4" horn) operated at 50% of full capacity to avoid overheating.
  • the whole cells were analyzed by SDS-PAGE.
  • the gene products derived from the TrpLE 18 hPTHrp (1-34)4 construct were seen as a major band of the predicted MW of approximately 17,000. This accounts for as much as 10% of the total cellular protein.
  • the cell lysate was centrifuged for 15 min. at about 3600 x g to pellet the Trp LE 18 hPTHrp (1-34) 4 fusion protein; the supernatant was discarded. The pellet was resuspended in 200 mL Tris buffer, (typically 40-80 A 550 /mL).
  • TrpLE 18 hPTHrp (1-34) 4 fusion protein was resuspended by gently stirring in 60 mL of 70% formic acid (about 20 mg/mL total protein; typically material from 1000 A 550 units of cells is dissolved in 3 mL) .
  • a few drops of octanol were added and N 2 bubbled through the solution for 20 minutes before adding 5.5 g CNBr.
  • This reaction was allowed to proceed for 6 hours at 25°C before an equal volume of 50:50 MeOH:Hp was mixed with the sample and subsequently removed by rotary evaporation. After 2 to 4 repetitions of this process, the bulk of the formic acid and CNBr were essentially removed.
  • the sample was then evaporated to dryness, redissolved in 200 mL water and lyophilized for storage.
  • the CNBr cleaved supernatant was dialyzed against 50 mM KH-PO 4 pH 6.5 for 24 hours with multiple changes. During dialysis, pH was maintained at 6.5. After dialysis, the precipitates were removed by high speed
  • Retention time of the homo-Serlactone hPTHrp (1-34), Compound 4 was approximately 2.943 minutes.
  • the purified peptide was approximately 98% pure as determined by mass spectroscopy.
  • EXAMPLE XI The compounds of this invention were evaluated for their effect on bone mass in ovariectomized rats, generally in accord with the procedures of Gunness-Hey and Hock, Metab. Bone Dis. 5:177 181 (1984).
  • the rats were sacrificed and the right femurs excised.
  • the femurs were cut in half and the distal half femurs (DHF) were further separated into trabecular bone (TB) and cortical bone
  • Calcette calcium analyzer and expressed as mean bone Ca in mg/DHF/100 g body weight.
  • the two sample t-test was used to compare OVX and sham groups.
  • Oneway ANOVA was used to compare OVX groups, followed by Fisher's LSD multiple comparison to compare each treatment group to vehicle.
  • Ovariectomy induced substantial total bone loss, primarily from trabecular bone.
  • Total bone calcium was 47 to 54% lower than for shamoperated controls.
  • bPTH(1-34) and hPTHrp (1-34) at 80 ⁇ g/kg/day provided statistically significant increases in total bone calcium for treated OVX rats, ranging from 53 to 95% and 18 to 40%, respectively; however, there was no

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Synthetic polypeptide analogs of parathyroid hormone PTH, parathyroid hormone related peptide PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, in which amino acid residues (22-31) form an amphipathic α-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence: Haa (Laa Laa Haa Haa)2 Laa and their pharmaceutically acceptable salts are useful for the prophylaxis and treatment of osteoporosis in mammals. Processes for the production of the polypeptides via solid phase and recombinant methods are provided.

Description

ANALOGS OF PARATHYROID HORMONE AND PARATHYROID HORMONE
RELATED PEPTIDE: SYNTHESIS AND USE FOR THE TREATMENT OF
OSTEOPOROSIS
BACKGROUND OF THE INVENTION a) Field of the Invention
This invention relates to novel analogs of parathyroid hormone and parathyroid hormone related peptide, their synthesis by solid phase and recombinant techniques, and their use for increasing bone mass in mammalian subjects. b) Description of Related Art Osteoporosis is the most common form of metabolic bone disease and may be considered the symptomatic, fracture stage of bone loss
(osteopenia). Although osteoporosis may occur secondary to a number of underlying diseases, 90% of all cases appear to be idiopathic.
Postmenopausal women are particularly at risk for idiopathic osteoporosis (postmeno-pausal or Type I osteoporosis). Another high risk group for idiopathic osteoporosis is the elderly of either sex (senile or Type II osteoporosis). Osteoporosis has also been related to corticosteroid use, immobilization or extended bed rest, alcoholism, diabetes, gonadotoxic chemotherapy, hyperprolactinemia, anorexia nervosa, primary and secondary amenorrhea, and oophorectomy.
In the various forms of osteoporosis, bone fractures, which are the result of bone loss that has reached the point of mechanical failure, frequently occur. Postmenopausal osteoporosis is characterized by fractures of the wrist and spine, while femoral neck fractures seem to be the dominant feature of senile osteoporosis.
The mechanism by which bone is lost in osteoporotics is believed to involve an imbalance in the process by which the skeleton renews itself.
This process has been termed bone remodeling. It occurs in a series of discrete pockets of activity. These pockets appear spontaneously within the bone matrix on a given bone surface as a site of bone resorption.
Osteoclasts (bone dissolving or resorbing cells) are responsible for the resorption of a portion of bone of generally constant dimension. This resorption process is followed by the appearance of osteoblasts (bone forming cells) which then refill with new bone the cavity left by the osteoclasts.
In a healthy adult subject, the rate at which osteoclasts and osteoblasts are formed is such that bone formation and bone resorption are in balance. However, in osteoporotics an imbalance in the bone remodeling process develops which results in bone being lost at a rate faster than it is being made. Although this imbalance occurs to some extent in most individuals as they age, it is much more severe and occurs at a younger age in postmenopausal osteoporotics or following oophorectomy.
There have been many attempts to treat osteoporosis with the goal of either slowing further bone loss or, more desirably, producing a net gain in bone mass. Certain agents, such as estrogen and the bisphosphonates, appear to slow further bone loss in osteoporotics. Agents which slow bone loss, because of the different durations of bone resorption and formation, may appear to increase bone mass (on the order of 3 to 7%) . However, this apparent increase is limited in time, not progressive, and is due to a decrease in "remodeling space." In addition, because of the close coupling between resorption and formation, treatments which impede bone resorption also ultimately impede bone formation.
It has been suggested that treatment with parathyroid hormone (PTH) would lead to both increased bone turnover and a positive calcium balance. However, human clinical trials have shown that any increase in trabecular bone is offset by a decrease in cortical bone, so that there is no net increase in total bone.
Hefti, et al. in Clinical Science 62, 389-396 (1982) have reported that daily subcutaneous doses of either bPTH(1-84) or hPTH(1-34) increased whole body calcium and ash weight of individual bones in both normal and osteoporotic adult female rats.
Liu, et al. in J. Bone Miner. Res. 6:10, 1071-1080 (1991) have noted that ovariectomy of adult female rats induced a 47% loss in the percentage of trabecular bone in the proximal tibial metaphysis, accompanied by a significant increase in the number of osteoblasts and trabecular
osteoclasts. Daily subcutaneous injections of hPTH(1-34) completely reversed the loss of trabecular bone and resulted in amounts of trabecular bone exceeding that of sham operated controls. The number of osteoblasts increased and the number of osteoclasts decreased.
Hock et al. in J. Bone Min. Res. 7:1, 65-71 (1992) have reported that daily subcutaneous injections of hPTH(1-34) to healthy adult male rats for 12 days increased trabecular and cortical bone calcium and dry weight.
Total bone mass, trabecular bone volume, trabecular thickness and number, and osteoblastic surfaces were increased.
The mammalian parathyroid hormones, e.g. human (hPTH), bovine (bPTH), and porcine (pPTH) , are single polypeptide chains of 84 amino acid residues, with molecular weights of approximately 9500. Biological activity is associated with the N-terminal portion, with residues (1-34) apparently the minimum required.
The N-terminal segment of human PTH differs from the
N-terminal segment of the bovine and porcine hormones by only three and two amino acid residues, respectively: hPTH(1-34 ) :
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu
1 5 10 15
Asn Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp
20 25 30
Val His Asn Phe (SEQ ID NO:1); bPTH(1-34)
Ala Val Ser Glu Ile Gln Phe Met His Asn Leu Gly Lys His Leu
1 5 10 15
Ser Ser Met Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp
20 25 30
Val His Asn Phe (SEQ ID NO:2); pPTH(1-34):
Ser Val Ser Glu Ile Gln Leu Met His Asn Leu Gly Lys His Leu
1 5 10 15
Ser Ser Leu Glu Arg Val Glu Trp Leu Arg Lys Lys Leu Gln Asp
20 25 30
Val His Asn Phe (SEQ ID NO:3)
The primary function of PTH is to elicit the adaptive changes that serve to maintain a constant concentration of Ca2+ in the extracellular fluid. PTH acts on the kidneys to increase tubular reabsorption of Ca2+ from the urine, as well as stimulating the conversion of calcifediol to calcitriol, which is responsible for absorption of Ca2+ from the
intestines. One prominent effect is to promote the mobilization of Ca2+ from bone. PTH acts on bone to increase the rate of resorption of Ca2+ and phosphate. PTH stimulates the rate of bone resorption by osteoclasts, increases the rate of differentiation of mesenchymal cells to osteoclasts, and prolongs the half life of these latter cells . With prolonged action of PTH the number of bone forming osteoblasts is also increased; thus, the rate of bone turnover and remodeling is enhanced. However, individual osteoblasts appear to be less active than normal.
Rosenblatt, et al. in U.S. Patent Nos. 4,423,037, 4,968,669 and 5,001,223 have disclosed PTH antagonists obtained by the deletion of the N-terminal (1-6) amino acids and the selective replacement of Phe7, Met8'18, and Gly12. Tyr34-NH2 reportedly increased the activity and stability of these compounds .
Parathyroid hormone-related peptide (PTHrp), a 140+ amino acid protein, and fragments thereof, reproduce the major biological actions of PTH. PTHrp is elaborated by a number of human and animal tumors and other tissues and may play a role in hypercalcemia of malignancy. The sequence of hPTHrp (1-34) is as follows: Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile 1 5 10 15
Gln Asp Leu Arg Arg Arg Phe Phe Leu His His Leu Ile Ala Glu
20 25 30
Ile His Thr Ala (SEQ ID NO:4) .
The sequence homology between hPTH and hPTHrp is largely limited to the 13 N-terminal residues, 8 of which are identical; only 1 of 10 amino acids in the (25-34) receptor binding region of hPTH is conserved in hPTHrp. Conformational similarity may underIle the common activity.
Cohen, et al. in J. Biol . Chem. 266:3, 1997-2004 (1991) have suggested that much of the sequence of PTH(1-34) and PTHrp (1-34), in particular regions (5-18) and (21-34), assumes an α-helical configuration, while noting that there is some question whether this configuration prevails for the carboxyl terminal end under physiological conditions. Such a secondary structure may be important for lipid interaction, receptor interaction, and/or structural stabilization.
We have synthesized analogs of PTH and of PTHrp with the objective of developing improved therapeutic agents for the restoration of bone mass in mammalian subjects, including those afflicted with osteoporosis.
SUMMARY OF THE INVENTION
This invention provides synthetic polypeptide analogs of parathyroid hormone (PTH) , parathyroid hormone related peptide (PTHrp) , and of the physiologically active truncated homologs and analogs of PTH and PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic cx-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:
Haa (Laa Laa Haa Haa)2 Laa. When specific illustrative embodiments of this sequence type are inserted into PTH, PTHrp, and the physiologically active truncated analogs and homologs of PTH and PTHrp, the resulting polypeptides are effective bone remodeling agents.
In one aspect, then, this invention provides analogs of PTH, PTHrp, and the physiologically active truncated analogs and homologs of PTH and
PTHrp, or salts thereof, in which amino acid residues (22-31) form an amphipathic α-helix, the sequence of said residues (22-31) selected from: a) Xaa1 Xaa2 Leu Xaa4 Xaa5 Leu Xaa7 Xaa8 Xaa9 Xaa10 wherein
1 5 10
Xaa1 and Xaa4 are independently Glu, Glu(OCH3), His, or Phe; Xaa2 is Leu or
Phe; Xaa5 is Lys or His; Xaa7 and Xaa10 are independently Leu or Ile; Xaa8 is
Ala, Arg, or Glu; and Xaa9 is Lys or Glu (SEQ ID NO:26); b) Xaa1 Xaa2 Leu Xaa4 Arg Leu Leu Xaa8 Arg Leu wherein
1 5 10
Xaa1 and Xaa4 are independently Glu, Glu(OCH3), His, or Phe; Xaa2 is Leu or Phe; Xaa8 is Glu, Lys, or Lys (COCR-PEGX) and PEGX is a poly- (ethylene glycol methyl ether) radical of molecular
weight 100 to 10,000 (SEQ ID NO:27);
c) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO: 28);
1 5 10
d) Ser Leu Leu Ser Ser Leu Leu Ser Ser Leu (SEQ ID NO:29);
1 5 10
e) Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu (SEQ ID NO: 30) .
1 5 10
In another aspect, this invention provides analogs of PTH, PTHrp, and the physiologically active truncated analogs and homologs of PTH and PTHrp, or salts thereof, of the formula:
Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Leu His Xaa10 Xaa11 Gly Xaa13 Ser Ile Gln Xaa17
Leu Xaa19 Xaa20 Xaa21 Xaa22-31 Xaa32 Xaa33 Xaa34 Xaa35 Xaa36 Xaa37 Xaa38 Term, wherein:
Xaa1 is absent or is Ala;
Xaa2 is absent or is Val;
Xaa3 is absent or is Ser;
Xaa4 is absent or is Glu or Glu (OCH-);
Xaa5 is absent or is His or Ala;
Xaa6 is absent or is Gln;
Xaa7 is absent or is Leu;
Xaa10 and Xaa17 are independently Asp or Asp (OCH3);
Xaa11 is Lys, Arg, or Leu;
Xaa13 is Lys, Arg, Tyr, Cys, Leu, Cys (CH2CONH (CH2) 2NH (biotinyl) ) , Lys (7-dimethylamino-2 -oxo-2H-l-benxopyran-4 -acetyl) , or Lys (dihydrocinnamoyl);
Xaa20 is Arg or Leu;
Xaa19 and Xaa21 are independently Lys, Ala, or Arg;
Xaa22-31 is selected from (SEQ ID NOS : 26 , 27 , 28 , 29 , or 30); Xaa32 is His ,
Pro, or Lys ;
Xaa33 is absent, or is Pro, Thr, Glu, or Ala;
Xaa34 is absent, or is Pro, Arg, Met, Ala, hSer, hSer lactone, Tyr, Leu, or 1 , 4 -diaminobutyryl lactam;
Xaa35 is absent or is Pro, Glu, Ser, Ala, or Gly;
Xaa36 is absent or is Ala, Arg, or Ile;
Xaa37 is absent or is Arg, Trp, or 3- (-2-naphthyl) -L-alanine;
Xaa38 is absent or is Ala or hSer or Xaa38j)2 is Thr Arg Ser Ala Trp;
and Term is OR or NR2 where each R is independently H, (C,-C4)alkyl or phenyl (C1-C4)alkyl; and the pharmaceutically acceptable salts thereof.
In yet another aspect, then, this invention provides analogs of PTH,
PTHrp, and of the physiologically active truncated homologs and analogs of
PTH and PTHrp, or salts thereof, in which amino acid residues (22-31) form an amphipathic α-helix, the sequence of said residues (22-31) selected from:
a) Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu wherein
1 5 10
Xaa is Glu or Arg (SEQ ID NO: 26);
b) Glu Leu Leu Glu Arg Leu Leu Xaa Arg Leu wherein
1 5 10
Xaa29 is Glu, Lys, or Lys (COCH-PEGX) and PEGX is a poly- (ethylene glycol methyl ether) radical of molecular weight 100 to 10,000 (SEQ ID NO:27); c) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO:28);
1 5 10
d) Ser Leu Leu Ser Ser Leu Leu Ser Ser Leu (SEQ ID NO: 29);
1 5 10
e) Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu (SEQ ID NO: 30) .
1 5 10
Also provided are pharmaceutical compositions for the prevention or treatment of conditions characterized by decreases in bone mass comprising an effective bone mass increasing amount of a polypeptide analog of parathyroid hormone (PTH) , parathyroid hormone related peptide (PTHrp) , and of the physiologically active truncated homologs and analogs of PTH and
PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic α-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence: Haa (Laa Laa Haa Haa), Laa. in admixture with a pharmaceutically acceptable carrier. Also provided are processes for preparing pharmaceutical compositions which comprise mixing the above described compounds with a pharmaceutically acceptable carrier.
Further, this invention provides methods for treating mammalian conditions characterized by decreases in bone mass which methods comprise administering to a mammal in need thereof an effective bone mass increasing amount of a polypeptide analog of PTH, PTHrp, or of a physiologically active truncated homolog or analog of PTH or PTHrp, or a salt thereof, in which amino acid residues (22-31) form an amphipathic α-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:
Haa (Laa Laa Haa Haa), Laa.
More specifically, this invention provides methods for treating mammalian conditions characterized by decreases in bone mass which methods comprise administering to a mammal in need thereof an effective bone mass increasing amount of a polypeptide analog of PTH, PTHrp, or of a
physiologically active truncated homolog or analog of PTH or PTHrp, or salt thereof, in which amino acid residues (22-31) form an amphipathic α-helix, the sequence of said residues (22-31) selected from: (SEQ ID NOS: 26, 27, 28, 29, and 30).
This invention also includes processes for the solid phase synthesis of polypeptide analogs of PTH, PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic α-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:
Haa (Laa Laa Haa Haa)2 Laa, which processes comprise sequentially coupling protected amino acids on a suitable resin support, removing the side chain and W-protecting groups, and cleaving the polypeptide from the resin.
This invention also encompasses processes for the solid phase synthesis of polypeptide analogs of PTH, pTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic α-helix, the sequence of said residues (22-31) selected from: (SEQ ID NOS: 26, 27, 28, 29, and 30); which processes comprise sequentially coupling protected amino acids on a suitable resin support, removing the side chain and Nα-protecting groups, and cleaving the polypeptide from the resin.
Also included are processes for the recombinant synthesis of
polypeptide analogs of PTH, PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic α-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) ordered in the sequence:
Haa (Laa Laa Haa Haa), Laa.
The invention also encompasses DNA sequences, vectors, and plasmids for the recombinant synthesis of such polypeptide analogs. Specifically, the invention provides DNA sequences, vectors, and plasmids for the recombinant synthesis of polypeptide analogs of PTH, PTHrp, and of the physiologically active truncated homologs and analogs of PTH and PTHrp, and salts thereof, in which amino acid residues (22-31) form an amphipathic α-helix, the sequence of said residues (22-31) selected from: (SEQ ID NOS: 26, 27, 28, 29, and 30). BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 presents the DNA sequence and enzyme restriction sites of a synthetic gene coding for a PTHrp (1-34) analog of this invention (hPTH PCR Amplification). Figure 2 outlines the preparation of a plasmid incorporating a
PTHrp(1-34) analog gene (Trp LE 18 hPTHrp (1-34) 1 Construction).
Figure 3 outlines the preparation of a plasmid incorporating two copies of a PTHrp(1-34) analog gene (Trp LE 18 hPTHrp (1-34) 2 Construction).
Figure 4 outlines the preparation of a plasmid incorporating four copies of a PTHrp(1-34) analog gene (Trp LE 18 hPTHrp (1-34) 4 Construct).
DETAILED DESCRIPTION OF THE INVENTION Abbreviations and Definitions
The one- and three-letter abbreviations for the various common nucleotide bases and amino acids are as recommended in Pure App2. Chem.
31, 639-645 (1972) and 40, 277-290 (1974) and comply with 37 CFR §1.822 (55
FR 18245, May 1, 1990), and with the PCT rules (WTPO Standard ST.23 :
Recommendation for the Presentation of Nucleotide and Amino Acid Sequences in Patent Applications and in Published Patent Documents) . The one- and three-letter abbreviations are as follows:
Amino Acid Abbreviations
Amino Acid Three-letter One-letter
Symbol Symbol
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic Acid Asp D
Asn + Asp Asx B
Cysteine Cys C
Glutamine Gln Q
Glutamic Acid Glu E
Gln + Glu Glx Z
Glycine Gly G
Histidine His H
Isoleucine Ile I
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V The abbreviations represent L-amino acids unless otherwise designated as D- or D,L-. Certain amino acids, both natural and non-natural, are achiral, e.g. glycine. All peptide sequences are presented with the N-terminal amino acid on the left and the C-terminal amino acid on the right.
Further abbreviations for other amino acids and compounds used herein are:
hSer homoserine
hSerlac homoserine lactone
Nle norleucine
PEG2 radical of diethylene glycol methyl
ether, a.k.a. methoxydi (ethyleneoxy),
CH3O (CH2CH2O)2-, (MW = 119)
PEG5000 radical of poly(ethylene glycol methyl
ether), a.k.a. methoxypoly (ethyleneoxy),
CH3O (CH2CH2O) 110- , (avg. MW = 5000)
PEGX radical of poly (ethylene glycol methyl
ether), CH3O(CH2CH2O)n- , n = 2 - 225,
(avg. MW = 100 to 10,000)
"Hydrophilic amino acid (Haa)" refers to an amino acid having at least one hydrophilic functional group in addition to those required for peptide bond formation, such as arginine, asparagine, aspartic acid, glutamic acid, glutamine, histidine, lysine, serine, threonine, and their homologs.
"Lipophilic amino acid (Laa)" refers to an uncharged, aliphatic or aromatic amino acid, such as isoleucine, leucine, methionine,
phenylalanine, tryptophan, tyrosine, valine, and their homologs.
For the purposes of this invention, alanine is classified as
"amphiphilic" i.e., capable of acting as either hydrophilic or lipophilic.
"Physiologically active truncated homolog or analog of PTH or PTHrp" refers to a polypeptide having a sequence comprising less than the full complement of amino acids found in PTH or PTHrp which, however, elicits a similar physiological response. The truncated PTH or PTHrp need not be fully homologous with PTH or PTHrp to elicit a similar physiological response. PTH (1-34) and PTHrp (1-34) are preferred, but not exclusive, representatives of this group.
"Amphipathic α-helix" refers to the secondary structure exhibited by certain polypeptides in which the amino acids assume an α-helical
configuration having opposing polar and nonpolar. faces oriented along the long axis of the helix. The possibility of α-helical structure in the polypeptide of interest may be explored to some extent by the construction of a "Schiffer-Edmundson wheel" (M. Schiffer and A. B. Edmundson,
Biophys. J. 7, 121 (1967)), of the appropriate pitch and noting the segregation of the hydrophilic and lipophilic residues on opposite faces of the cylinder circumscribing the helix. Alternatively, empirical evidence, such as circular dichroism or x-ray diffraction data, may be available indicating the presence of an α-helical region in a given polypeptide. An ideal α-helix has 3.6 amino acid residues per turn with adjacent side chains separated by 100° of arc. Eisenberg et al. in Nature 299:371-374 (1982) and Proc. Nat. Acad. Sci . USA 81:140-144 (1984) have combined a hydrophobicity scale with the helical wheel to quantify the concept of amphipathic helices. The mean hydrophobic moment is defined as the vector sum of the hydrophobicities of the component amino acids making up the helix. The following hydrophobicities for the amino acids are those reported by Eisenberg (1984) as the "consensus" scale:
Ile 0.73; Phe 0.61; Val 0.54; Leu 0.53; Trp 0.37;
Met 0.26 Ala 0.25; Gly 0.16; Cys 0.04; Tyr 0.02;
Pro -0.07; Thr -0.18; Ser -0.26; His -0.40; Glu -0.62;
Asn -0.64; Gln -0.69; Asp -0.72; Lys -1.10; Arg -1.76.
The hydrophobic moment, μH, for an ideal α-helix having 3.6 residues per turn (or a 100° arc ( = 360°/3.6) between side chains), may be calculated from:
μH = [ ( ∑ HNsinδ(N-1) )2 + ( Σ HNcosδ(N-1) )2 ] ½,
where HN is the hydrophobicity value of the N* amino acid and the sums are taken over the N amino acids in the sequence with periodicity δ=100° . The hydrophobic moment may be expressed as the mean hydrophobic moment per residue by dividing μH by N to obtain <μH>. A value of <μH> at 100° ± 20° of about 0.20 or greater is suggestive of amphipathic helix formation. The <μH> values at 100° for hPTHrp (22-31) and hPTH (22-31) are 0.19 and 0.37, respectively.
Cornett, et al., in J. Mol . Biol . , 195:659-685 (1987) have further extended the study of amphiphathic α-helices by introducing the
"amphipathic index" as a predictor of amphipathicity. They concluded that approximately half of all known α-helices are amphipathic, and that the dominant frequency is 97.5° rather than 100°, with the number of residues per turn being closer to 3.7 than 3.6. While such refinements are scientifically interesting, the basic approach of Eisenberg, et al. is sufficient to classify a given sequence as amphipathic, particularly when one is designing a sequence ab initio to form an amphipathic
α-helix.
A substitute amphipathic α-helical amino acid sequence may lack homology with the sequence of a given segment of a naturally occurring polypeptide but elicits a similar secondary structure, i. e. an α-helix having opposing polar and nonpolar faces, in the physiological environment. Replacement of the naturally occurring amino acid sequence with an alternative sequence may beneficially affect the physiological activity, stability, or other properties of the altered parent polypeptide. Guidance as to the design and selection of such sequences is provided in J. L.
Krstenansky, et al., FEBS Letters 242:2, 409-413 (1989), and J. P. Segrest, et al. Proteins: Structure, Function, and Genetics 8:103-117 (1990) among others. The ten amino acid amphipathic α-helix of this invention has the formula:
Haa (Laa Laa Haa Haa)2 Laa
wherein the Haa's are selected from the group of hydrophilic amino acids and the Laa's are selected from the group of lipophilic amino acids, as defined above. Assuming an idealized α-helix, residues 1, 4, 5, 8, and 9 are distributed along one face (A) of the helix within about a 140° arc of each other, while residues 2, 3, 6, 7, and 10 occupy an opposing 140° arc on the other face (B) of the helix. Preferably, all the residues on one face are of the same polarity while all those on the other face are of the opposite polarity, i.e., if face A is all hydrophilic, face B is all lipophilic and vice versa. The skilled artisan will recognize that while the helices of this invention are described by Haa (Laa Laa Haa Haa)2 Laa,
the reverse sequence,
Laa (Haa Haa Laa Laa)2 Haa will also meet the residue distribution criteria and is an equivalent descriptor of the helices of this invention.
Alanine may be substituted for either hydrophilic or lipophilic amino acids, since Ala can reside readily on either face of an amphipathic α-helix, although Ala10 does not form an amphipathic α-helix. Generally, proline, cysteine, and tyrosine are not used; however, their presence and other random errors in the sequence may be tolerated, e.g. a hydrophilic residue on the lipophilic face, as long as the remaining amino acids in the segment substantially conform to the hydrophilic face - lipophilic face division. A convenient method for determining if a sequence is
sufficiently amphipathic to be a sequence of this invention is to calculate the mean hydrophobic moment, as defined above. If the peak mean moment per residue at 100° ± 20° exceeds about 0 .20 , then the sequence will form an amphipathic helix and is a sequence of this invention.
For example, the mean hydrophobic moment per residue at 100° for (SEQ ID NO: 26), Xaa = Glu, is calculated as follows:
A.A. HN δ (N-1) H sin δ(N-1) H cos δ(N-1)
E -.62 0 0 -.62
L .53 100 .52 -.17
L .53 200 -.18 -.50
E -.62 300 .34 -.31
K -1.1 400 -.70 -.85
L .53 500 .34 - .41
L .53 600 -.46 -.27
E -.62 700 .21 -.58
K -1.1 800 -1.08 -.19
L .53 900 0 -.53
∑=0.81 ∑=-4.43
μH = [(0.81)2 + (-4.43)2]½ = 4.50
< μH > = 4.50/10 = 0.45
For this sequence, the mean peak hydrophobic moment occurs at 92° and has a value of 0.48.
In applying this concept to parathyroid hormone and parathyroid hormone related peptide, it was hypothesized that either or both regions (7-16) and (22-31) may exhibit α-helical secondary structure and could be replaced with a non-homologous sequence having similar structural
tendencies, without loss of biological activity or induction of
immunoreaction . Preferred Embodiments
In one aspect, this invention provides analogs of PTH, PTHrp, and the physiologically active truncated analogs and homologs of PTH and PTHrp, or salts thereof, in which amino acid residues (22-31) form an amphipathic α-helix, the sequence of said residues (22-31) selected from:
a) Xaa1 Xaa2 Leu Xaa4 Xaa5 Leu Xaa7 Xaa8 Xaa9 Xaa10 wherein
1 5 10
Xaa1 and Xaa4 are independently Glu, Glu(0CH3), His, or Phe; Xaa2 is Leu or Phe; Xaa5 is Lys or His; Xaa7 and Xaa10 are independently Leu or Ile; Xaa8 is Ala, Arg, or Glu; and Xaa9 is Lys or Glu (SEQ ID NO:26);
b) Xaa1 Xaa2 Leu Xaa4 Arg Leu Leu Xaa8 Arg Leu wherein
1 5 10
Xaa1 and Xaa4 are independently Glu, Glu(OCH3), His, or Phe; Xaa2 is Leu or Phe; Xaa8 is Glu, Lys, or Lys (COCH2PEGX) and PEGX is a poly- (ethylene glycol methyl ether) radical of molecular
weight 100 to 10,000 (SEQ ID NO:27);
c) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO:28);
1 5 10
d) Ser Leu Leu Ser Ser Leu Leu Ser Ser Leu (SEQ ID NO:29);
1 5 10
e) Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu (SEQ ID NO:30).
1 5 10
In another aspect, this invention provides analogs of PTH, PTHrp, and the physiologically active truncated analogs and homologs of PTH and PTHrp, or salts thereof, of the formula:
Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa6 Xaa7 Leu His Xaa10 Xaa11 Gly Xaa13 Ser Ile Gln Xaa17
Leu Xaa19 Xaa20 Xaa21 Xaa22-31 Xaa32 Xaa33 Xaa34 Xaa35 Xaa36 Xaa37 Xaa38 Term, wherein :
Xaa1 is absent or is Ala;
Xaa2 is absent or is Val ;
Xaa3 is absent or is Ser ;
Xaa4 is absent or is Glu or Glu (OCH3);
Xaa5 is absent or is His or Ala;
Xaa6 is absent or is Gln;
Xaa7 is absent or is Leu;
Xaa10 and Xaa17 are independently Asp or Asp (OCH3);
Xaa11 is Lys , Arg, or Leu;
Xaa13 is Lys , Arg, Tyr, Cys , Leu, Cys (CH2CONH (CH2) 2NH (biotinyl) ) , Lys (7 -dimethylamino-2 -oxo-2H- 1 -benxopyran-4 -acetyl) , or Lys (dihydrocinnamoyl); Xaa20 is Arg or Leu;
Xaa19 and Xaa21 are independently Lys , Ala, or Arg;
Xaa22"31 is selected from (SEQ ID NOS : 26 , 27 , 28 , 29 , or 30); Xaa32 is His ,
Pro, or Lys ;
Xaa33 is absent, or is Pro, Thr, Glu, or Ala;
Xaa34 is absent, or is Pro, Arg, Met, Ala, hSer, hSer lactone, Tyr, Leu, or
1,4-diaminobutyryl lactam;
Xaa35 is absent or is Pro, Glu, Ser, Ala, or Gly;
Xaa36 is absent or is Ala, Arg, or Ile;
Xaa37 is absent or is Arg, Trp, or 3- (-2-naphthyl) -L-alanine;
Xaa38 is absent or is Ala or hSer or Xaa3iM2 is Thr Arg Ser Ala Trp;
and Term is OR or NR- where each R is independently H, (C,-C4)alkyl or phenyl (C1-C4)alkyl; and the pharmaceutically acceptable salts thereof.
In yet another aspect this invention includes polypeptide analogs of the physiologically active truncated homolog hPTHrp (1-34) , as shown in Formula (I) :
Ala Val Ser Glu Xaa5 Gln Leu Leu His Asp Xaa11 Gly Xaa13 Ser Ile Gln Asp Leu
Xaa19 Arg Xaa21 Xaa22-31 Xaa32 Xaa33 Xaa34 Term, wherein:
Xaa5 is His or Ala;
Xaa11 and Xaa13 are independently Lys, Arg, or Leu; Xaa19 and Xaa21 are independently Ala or Arg;
Xaa22-31 is selected from:
a) Glu Leu Leu Glu Lys Leu Leu Xaa Lys Leu wherein
1 5 10
Xaa is Glu or Arg (SEQ ID NO:26);
b) Glu Leu Leu Glu Arg Leu Leu Xaa Arg Leu wherein
1 5 10
Xaa is Glu, Lys, or Lys (COCHjPEGX) and PEGX is a
poly (ethylene glycol methyl ether) radical of molecular
weight 100 to 10,000 (SEQ ID NO:27);
c) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO: 28);
1 5 10
d) Ser Leu Leu Ser Ser Leu Leu Ser Ser Leu (SEQ ID NO: 29);
1 5 10
Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu (SEQ ID NO: 30);
1 5 10
Xaa32 is His or Lys;
Xaa33 is Thr, Glu, or Ala;
Xaa34 is Ala, hSer, Tyr, or Leu;
and Term is Gly Arg Arg, lactone, OH or NR2, where each R is H or (C1-C4) alkyl; and their pharmaceutically acceptable salts. (Formula I)
A more specific aspect of the invention includes
those polypeptides of Formula (I) wherein Xaa22-31 is (SEQ ID NO:26) , for which <μH> at 100° exceeds 0.45. A still more specific aspect of the invention includes those Formula (I) polypeptides wherein Xaa22-31 is (SEQ ID NO: 26); Xaa11 and Xaa13 are both Lys; and Xaa19 and Xaa21 are both Arg.
Representative polypeptides include, but are not limited to:
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Arg Lys
20 25 30 Leu His Thr Ala OH (SEQ ID NO:5);
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr Ala OH (SEQ ID NO: 6); Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr Ala NH2 (SEQ ID NO: 7); Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr hSer NH2 (SEQ ID NO: 8);
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr hSerlac (SEQ ID NO: 9);
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr Ala Gly Arg Arg OH (SEQ ID NO: 10); and
35
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu Lys Glu Leu NH2 (SEQ ID NO: 11).
Another aspect of this invention includes those polypeptides of Formula (I) wherein Xaa22-31 is (SEQ ID NO:26); Xaa11 and Xaa13 are both Lys; and one of Xaa19 and Xaa21 is Arg and the other is Ala. Representative poly-peptides of this subgenus include, but are not limited to:
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser He
1 5 10 15
Gln Asp Leu Ala Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr Ala NH2 (SEQ ID NO: 12) and Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile 1 5 10 15
Gln Asp Leu Arg Arg Ala Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr Ala NH2 (SEQ ID NO: 13) . In another aspect this invention includes those polypeptides of
Formula (I) wherein Xaa22-31 is (SEQ ID NO:26); one of Xaa11 and Xaa13 is Leu and the other is Lys; and Xaa19 and Xaa21 are both Arg. Representative polypeptides of this subgenus include , but are not limited to :
Ala Val Ser Glu Ala Gln Leu Leu His Asp Leu Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Ala Leu OH (SEQ ID NO: 14)
In another aspect this invention includes those polypeptides of Formula (I) wherein Xaa22-31 is (SEQ ID N0:27) , for which <μH> at 100° exceeds 0.50. A further aspect of this invention includes those Formula (I) polypeptides wherein Xaa22-31 is (SEQ ID NO:27); Xaa11 and Xaa13 are both Lys or both Arg; and Xaa19 and Xaa21 are both Arg. Representative polypeptides of this subgenus include, but are not limited to:
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu Glu Arg
20 25 30
Leu His Thr Ala OH (SEQ ID NO: 15);
Ala Val Ser Glu His Gln Leu Leu His Asp Arg Gly Arg Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu Glu Arg
20 25 30
Leu His Thr Ala OH (SEQ ID NO: 16);
Ala Val Ser Glu His Gln Leu Leu His Asp Arg Gly Arg Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu Lys Arg
20 25 30
Leu His Thr Ala OH (SEQ ID NO: 17); Ala Val Ser Glu His Gln Leu Leu His Asp Arg Gly Arg Ser Ile 1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu
20 25
Lys (COCH-PEG2 ) Arg Leu His Thr Ala OH (SEQ ID NO : 18); and
30
Ala Val Ser Glu His Gln Leu Leu His Asp Arg Gly Arg Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Arg Leu Leu
20 25
Lys(COCH2PEG5000) Arg Leu His Thr Ala OH (SEQ ID NO:19) .
30
In another aspect this invention includes polypeptides of Formula (I) wherein Xaa22-31 is (SEQ ID NO:28) , for which <μH> at 100° is about 0.25. Representative polypeptides of this subgenus include, but are not limited to:
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Ala Leu Ala Glu Ala Leu Ala Glu Ala
20 25 30
Leu His Thr Ala NH2 (SEQ ID NO:20)
In another aspect this invention includes polypeptides of Formula (I) wherein Xaa22-31 is (SEQ ID NO:29) , for which <μH> at 100° is about 0.28.
Representative polypeptides of this subgenus include, but are not limited to:
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Ser Leu Leu Ser Ser Leu Leu Ser Ser
20 25 30
Leu His Thr Ala NH2 (SEQ ID NO:21) .
In another aspect this invention includes polypeptides of Formula (I) wherein Xaa22-31 is (SEQ ID NO:30) , for which <μH> at 100° is about 0.29. Representative polypeptides of this subgenus include, but are not limited to:
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Ala Phe Tyr Asp Lys Val Ala Glu Lys
20 25 30
Leu His Thr Ala NH2 (SEQ ID NO:22) . Still another aspect of this invention includes polypeptide analogs of the physiologically active truncated homolog bPTH(1-34), as shown in
Formula (II) :
Xaa1 Val Ser Glu Ile Gln Xaa7 Xaa8 His Asn Leu Gly Lys His Leu Xaa16 Ser Xaa18 Xaa19 Arg Xaa21 Xaa22-31 His Asn Xaa34 Term, wherein:
Xaa1 is Ser or Ala;
Xaa7 is Leu or Phe ;
Xaa8 is Met or Nle ;
Xaa16 is Asn or Ser;
Xaa18 is Leu, Met, or Nle ;
Xaa19 is Glu or Arg;
Xaa21 is Val or Arg;
Xaa22-31 is selected from (SEQ ID NO : 26 , 27 , 28, 29 , and 30);
Xaa34 is Phe or Tyr;
Term is OH or NR2, where each R is H or (C1-C4) alkyl ; and the
pharmaceutically acceptable salts thereof . (Formula II)
Representative polypeptides include, but are not limited to :
Ala Val Ser Glu Ile Gln Phe Nle His Asn Leu Gly Lys His Leu
1 5 10 15
Ser Ser Nle Glu Arg Val Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Asn Tyr NH2 (SEQ ID NO: 23) and
Ala Val Ser Glu Ile Gln Phe Nle His Asn Leu Gly Lys His Leu
1 5 10 15
Ser Ser Nle Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Asn Tyr NH2 (SEQ ID NO: 24) .
In still another aspect of this invention, it has surprisingly been found that homologs and analogs of PTH and PTHrP having less than 34 amino acids are also potent bone remodeling agents . These compounds are of general formula:
Ala Val Ser Glu Xaa5 Gln Leu Leu His Asp Xaa11 Gly Xaa13 Ser Ile Gln Asp Leu Xaa19 Arg Xaa21 Xaa22-31 Xaa32 Xaa33 Xaa34 Term,
Representative polypeptides include, but are not limited to:
Compound 41: AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LHP-NH2 (SEQ ID NO: 55)
Physical Data
m.p. 142.8-166.1°C [α]D 25 -53 .80 (c 0 .38, H2O)
FAB (C173H295N55O49) : [M+H] + 3929
AAA: Asx 2.0 (2) Glx 5.7 (6) Ser 1.8 (2)
His 3.0 (3) Gly 1.1 (1) Ala 0.9 (1)
Arg 2.8 (3) Val 1.2 (1) Ile 0.9 (1)
Leu 7.4 (8) Lys 4.4 (4) Pro 0.9 (1) Compound 42: AVSEHQLLHD KGKSIQDLRR RELLEKLLEK LP-NH2 (SEQ ID NO: 56)
Physical Data
m.p. 161.0-177.0°C [α]D 25 -61.97 (c 0.19, H2O)
FAB (C16H288N52O48) : [M+H] + 3792.0
AAA: Asx 2.2 (2) Glx 5.9 (6) Ser 1.9 (2)
His 2.1 (2) Gly 1.1 (1) Ala 1.0 (1)
Arg 3.0 (3) Val 1.1 (1) Ile 1.0 (1)
Leu 7.9 (8) Lys 4.3 (4) Pro 0.9 (1) The skilled artisan will appreciate that numerous permutations of the polypeptide analogs may be synthesized which will possess the desirable attributes of those described herein provided that an amino acid sequence having a mean hydrophobic moment per residue at 100° ± 20° greater than about 0.20 is inserted at positions (22-31).
Classical Synthesis of the Polypeptides
The polypeptides of the instant invention may be synthesized by methods such as those set forth in
J.M. Stewart and J.D. Young, Solid Phase Peptide Synthesis, 2nd ed., Pierce Chemical Co., Rockford, Illinois (1984) and J. Meienhofer, Hormonal
Proteins and Peptides, Vol. 2, Academic Press, New York, (1973) for solid phase synthesis and E. Schroder and K. Lubke, The Peptides, Vol. 1,
Academic Press, New York, (1965) for solution synthesis.
In general, these methods involve the sequential addition of protected amino acids to a growing peptide chain. Normally, either the amino or carboxyl group of the first amino acid and any reactive side chain group are protected. This protected amino acid is then either attached to an inert solid support, or utilized in solution, and the next amino acid in the sequence, also suitably protected, is added under conditions amenable to formation of the amide linkage . After all the desired amino acids have been linked in the proper sequence, protecting groups and any solid support are removed to afford the crude polypeptide. The polypeptide is desalted and purified, preferably chromatographically, to yield the final product.
A preferred method of preparing the analogs of the physiologically active truncated polypeptides, having fewer than about forty amino acids, involves solid phase peptide synthesis. In this method the α-amino (Nα) functions and any reactive side chains are protected by acid- or
base-sensitive groups. The protecting group should be stable to the conditions of peptide linkage formation, while being readily removable without affecting the extant polypeptide chain. Suitable α-amino
protecting groups include, but are not limited to t-butoxycarbonyl (Boc), benzyloxycarbonyl (Cbz), o-chlorobenzyloxycarbonyl,
biphenylisopropyloxycarbonyl, t-amyloxycarbonyl (Amoc), isobornyloxycarbonyl, α,α-dimethyl-3,5-dimethoxybenzyloxy-carbonyl, o-nitrophenylsulfenyl, 2-cyano-t.-butoxycarbonyl, 9-fluorenylmethoxycarbonyl (Fmoc) and the like, preferably t-butoxycarbonyl (Boc). Suitable side chain protecting groups include, but are not limited to: acetyl, benzyl (Bzl), benzyloxymethyl (Bom), o-bromobenzyloxycarbonyl, t-butyl,
t-butyldimethylsilyl, 2-chlorobenzyl (Cl-z), 2,6-dichlorobenzyl,
cyclohexyl, cyclopentyl, isopropyl, pivalyl, tetrahydropyran-2-yl, tosyl (Tos), trimethylsilyl, and trityl.
In solid phase synthesis, the C-terminal amino acid is first attached to a suitable resin support. Suitable resin supports are those materials which are inert to the reagents and reaction conditions of the stepwise condensation and deprotection reactions, as well as being insoluble in the media used. Examples of commercially available resins include
styrene/divinylbenzene resins modified with a reactive group, e.g., chloromethylated co-poly-(styrene-divinylbenzene), hydroxymethylated co-poly-(styrene-divinylbenzene), and the like. Benzylated, hydroxymethylated phenylacetamidomethyl (PAM) resin is preferred. When the
C-terminus of the compound is an amide, a preferred resin is
p-methylbenzhydrylamino-co-poly(styrene-divinyl-benzene) resin.
Attachment to the PAM resin may be accomplished by reaction of the
ΪT-protected amino acid, preferably the Boc-amino acid, as its ammonium, cesium, triethylammonium, 1,5-diazabicyclo-[5.4.0]undec-5-ene,
tetramethylammonium, or similar salt in ethanol, acetonitrile,
N,N-dimethylformamide (DMF), and the like, preferably the cesium salt in DMF, with the resin at an elevated temperature, for example between about 40° and 60°C, preferably about 50°C, for from about 12 to 72 hours, preferably about 48 hours.
The Nα-Boc-amino acid may be attached to the benzhydrylamine resin by means of, for example, an N,N'-diisopropylcarbodiimide
(DIC) /1-hydroxybenzotriazole (HOBt) mediated coupling for from about 2 to about 24 hours, preferably about 2 hours at a temperature of between about 10° and 50°C, preferably 25°C in a solvent such as dichloro-methane or dimethylformamide, preferably dichloromethane.
The successive coupling of protected amino acids may be carried out by methods well known in the art, typically in an automated peptide synthesizer. Following neutralization with triethylamine or similar base, each protected amino acid is preferably introduced in approximately 1.5 to 2.5 fold molar excess and the coupling carried out in an inert, nonaqueous, polar solvent such as dichloromethane, DMF, or mixtures thereof, preferably in dichloromethane at ambient temperature. Representative coupling agents are N,N' -dicyclohexylcarbodiimide (DCC) , N,N'-diisopropyl-carbodiimide (DIC) or other carbodiimide, either alone or in the presence of
1-hydroxybenzotriazole (HOBt), O-acyl ureas,
benzotriazol-1-yl-oxytris (pyrrolidino)phosphonium hexafluorophosphate (PyBop), N-hydroxysuccinimide, other N-hydroxyimides, or oximes. Alternatively, protected amino acid active esters (e.g. p-nitrophenyl, pentafluorophenyl and the like) or symmetrical anhydrides may be used.
At the end of the solid phase synthesis the fully protected peptide is removed from the resin. When the linkage to the resin support is of the benzyl ester type, cleavage may be effected by means of aminolysis with an alkylamine or fluoroalkylamine for peptides with an alkylamide C-terminus, or by aminolysis with, for example, ammonia/methanol or ammonia/ethanol for peptides with an unsubstituted amide C-terminus, at a temperature between about -10° and 50°C, preferably about 25°C, for between about 12 and 24 hours, preferably about 18 hours. Peptides with a hydroxy C-terminus may be cleaved by HF or other strongly acidic deprotection regimen or by saponification. Alternatively, the peptide may be removed from the resin by transesterification, e.g., with methanol, followed by aminolysis or saponification. The protected peptide may be purified by silica gel chromatography.
The side chain protecting groups may be removed from the peptide by treating the aminolysis product with, for example, anhydrous liquid hydrogen fluoride in the presence of anisole or other carbonium ion scavenger, treatment with hydrogen fluoride/pyridine complex, treatment with tris(trifluoroacetyl) boron and trifluoroacetic acid, by reduction with hydrogen and palladium on carbon or polyvinylpyrrolidone, or by reduction with sodium in liquid ammonia, preferably with liquid hydrogen fluoride and anisole at a temperature between about -10° and +10°C, preferably at about 0°C, for between about 15 minutes and 2 hours, preferably about 1.5 hours.
For peptides on the benzhydrylamine resin, the resin cleavage and deprotection steps may be combined in a single step utilizing liquid hydrogen fluoride and anisole as described above.
The solution may be desalted (e.g. with BioRad AG-3® anion exchange resin) and the peptide purified by a sequence of chromatographic steps employing any or all of the following types: ion exchange on a weakly basic resin in the acetate form; hydrophobic adsorption chromatography on underivatized co-poly (styrene-divinylbenzene), e.g.. Amberlite® XAD; silica gel adsorption chromatography; ion exchange chromatography on
carboxymethylcellulose; partition chromatography, e.g. on Sephadex® G-25; countercurrent distribution; or high performance liquid chromatography
(HPLC), especially reversed-phase HPLC on octyl- or octadecylsilylsilica (ODS) bonded phase column packing.
Thus, another aspect of the present invention relates to processes for preparing polypeptides and pharmaceutically acceptable salts thereof which processes comprise sequentially condensing protected amino acids on a suitable resin support, removing the protecting groups and resin support, and purifying the product, to afford analogs of the physiologically active truncated homologs and analogs of PTH and PTHrp, preferably of PTH(1-34) and PTHrp(1-34), in which the amino acids at positions (22-31) form an amphipathic α-helical peptide sequence, as defined above. Recombinant Synthesis of the Polypeptides
Alternatively, the polypeptides of this invention may be prepared by cloning and expression of a gene encoding for the desired polypeptide. In this process, a plasmid containing the desired DNA sequence is prepared and inserted into an appropriate host microorganism, typically a bacteria, such as E. coli, or a yeast, such as Saccharomyces cerevisiae, inducing the host microorganism to produce multiple copies of the plasmid, and so of the cDNA encoding for the polypeptide analogs of this invention.
First, a synthetic gene coding for the selected
PTH or PTHrp analog is designed with convenient restriction enzyme cleavage sites to facilitate subsequent alterations. Polymerase chain reaction (PCR), as taught by Mullis in U. S. Patent Nos. 4,683,195 and 4,683,202, may be used to amplify the sequence.
The amplified synthetic gene may be isolated and ligated to a suitable plasmid, such as a Trp LE plasmid, into which four copies of the gene may be inserted in tandem. Preparation of Trp LE plasmids is described in U.S. Patent No. 4,738,921 and European Patent Publication No. 0212532. Trp LE plasmids generally produce 8-10 times more protein than Trp E plasmids. The multi-copy gene may then be expressed in an
appropriate host, such as E. coli or S. cerevisiae.
The specific expression vector used herein was Trp LE 18 Prot (Ile3, Pro5) containing the following elements: a pBR322 fragment (EcoRI-BamHI) containing the ampicillin resistant gene and the plasmid origin of replication; an EcoRI-SacII fragment containing the trp promoter and the trpE gene; an HIV protease (Ile3, Pro5) gene fragment (SacII-HindIII); a bGRF gene fragment (HindIII-BamHI); and a transcription terminator from E. coli rpoc gene. The HIV protease and bGRF gene fragments are not critical and may be replaced with other coding sequences, if desired.
The expressed multimeric fusion proteins accumulate intracellularly into stable inclusion bodies and may be separated by centrifugation from the rest of the cellular protein. The isolated fusion protein is converted to the monomeric PTH or PTHrp analog and may be purified by cation exchange and/or reverse phase HPLC.
Alternative methods of cloning, amplification, expression, and purification will be apparent to the skilled artisan. Representative methods are disclosed in Maniatis, et al., Molecular Cloning, a Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory (1989). Utility and Administration
The polypeptides of this invention are useful for the prevention and treatment of a variety of mammalian conditions manifested by loss of bone mass. In particular, the compounds of this invention are indicated for the prophylaxis and therapeutic treatment of osteoporosis and osteopenia in humans.
In general, the polypeptides of this invention, or salts thereof, are administered in amounts between about 0.002 and 1 μg/kg body weight per day, preferably from about 0.04 to about 0.2 μg/kg body weight per day. For a 50 kg human female subject, the daily dose of active ingredient is from about 0.1 to about 50 μgs, preferably from about 2.0 to about 10 μgs. In other mammals, such as horses, dogs, and cattle, higher doses may be required. This dosage may be delivered in a conventional pharmaceutical composition by a single administration, by multiple applications, or via controlled release, as needed to achieve the most effective results, preferably one or more times daily by injection.
The selection of the exact dose and composition and the most appropriate delivery regimen will be influenced by, inter alia, the pharmacological properties of the selected polypeptide, the nature and severity of the condition being treated, and the physical condition and mental acuity of the recipient.
Representative delivery regimens include oral, parenteral (including subcutaneous, intramuscular and intravenous), rectal, buccal (including sublingual), pulmonary, transdermal, and intranasal.
Pharmaceutically acceptable salts retain the desired biological activity of the parent polypeptide without toxic side effects. Examples of such salts are (a) acid addition salts formed with inorganic acids, for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like; and salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acids, naphthalene disulfonic acids,
polygalacturonic acid and the like; (b) base addition salts formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel, cadmium, and the like; or with an organic cation formed from N,N'-dibenzylethylenediamine or ethylenediamine; or (c) combinations of (a) and (b), e.g., a zinc tannate salt and the like.
A further aspect of the present invention relates to pharmaceutical compositions comprising as an active ingredient a polypeptide of the present invention, or pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable, non-toxic carrier. As mentioned above, such compositions may be prepared for parenteral
(subcutaneous, intramuscular or intravenous) administration, particularly in the form of liquid solutions or suspensions; for oral or buccal administration, particularly in the form of tablets or capsules; for pulmonary or intranasal administration, particularly in the form of powders, nasal drops or aerosols; and for rectal or transdermal
administration. The compositions may conveniently be administered in unit dosage form and may be prepared by any of the methods well-known in the pharmaceutical art, for example as described in Remington 's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA., (1985). Formulations for parenteral administration may contain as excipients sterile water or saline, alkylene glycols such as propylene glycol, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, hydrogenated naphthalenes and the like. For oral administration, the formulation can be enhanced by the addition of bile salts or acylcarnitines. Formulations for nasal administration may be solid and may contain excipients, for example, lactose or dextran, or may be aqueous or oily solutions for use in the form of nasal drops or metered spray. For buccal administration typical excipients include sugars, calcium stearate, magnesium stearate,
pregelatinated starch, and the like.
When formulated for nasal administration, the absorption across the nasal mucous membrane may be enhanced by surfactant acids, such as for example, glycocholic acid, cholic acid, taurocholic acid, ethocholic acid, deoxycholic acid, chenodeoxycholic acid, dehydrocholic acid,
glycodeoxycholic acid, cyclodextrins and the like in an amount in the range between about 0.2 and 15 weight percent, preferably between about 0.5 and 4 weight percent, most preferably about 2 weight percent.
Delivery of the compounds of the present invention to the subject over prolonged periods of time, for example, for periods of one week to one year, may be accomplished by a single administration of a controlled release system containing sufficient active ingredient for the desired release period. Various controlled release systems, such as monolithic or reservoir-type microcapsules, depot implants, osmotic pumps, vesicles, micelles, liposomes, transdermal patches, iontophoretic devices and alternative injectable dosage forms may be utilized for this purpose.
Localization at the site to which delivery of the active ingredient is desired is an additional feature of some controlled release devices, which may prove beneficial in the treatment of certain disorders.
One form of controlled release formulation contains the polypeptide or its salt dispersed or encapsulated in a slowly degrading, non-toxic, non-antigenic polymer such as copoly (lactic/glycolic) acid, as described in the pioneering work of Kent, Lewis, Sanders, and Tice, U.S. 4,675,189. The compounds or, preferably, their relatively insoluble salts, may also be formulated in cholesterol or other lipid matrix pellets, or silastomer matrix implants. Additional slow release, depot implant or injectable formulations will be apparent to the skilled artisan. See, for example,
Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson ed., Marcel Dekker, Inc., New York, 1978, and R. W. Baker, Controlled Release of Biologically Active Agents, John Wiley & Sons, New York, 1987.
The following specific Examples are intended to illustrate the synthesis and testing of representative compounds of the invention and should not be construed as limiting the scope of the claims . In the Examples, "m. p." is melting point, "[α]D 25" is the optical activity at 25°C at the given concentration in the indicated solvent, "FAB" is fast atom bombardment mass spectrometry, and "AAA" is amino acid analysis, with expected values in parentheses following the observed values. The amino acid analyses were conducted on a Hewlett-Packard AminoQuant Analyzer following the manufacturer' s recommended protocols. Primary amino acids were derivatized with o-phthalaldehyde; secondary amino acids with Fmoc. Fluorescent detection of the derivatized amino acids was used for
quantification. The protected amino acids were obtained from Applied Biosystems Inc. (Foster City, CA) .
EXAMPLE I Compound 1 (SEQ ID NO: 7) was prepared on 0.5 mmol scale by the solid phase method on 4-methylbenzhydrylamine resin, using an automated Applied Biosystems Model 430A peptide synthesizer. The α-amino groups were protected with t-butoxycarbonyl (Boc) . The side chain protecting groups were: benzyl (Bzl) for Asp, Glu, and Ser; tosyl (Tos) for Arg;
benzyloxymethyl (Bom) for His; and 2-chlorobenzyl (Cl-z) for Lys. The amino acids were coupled sequentially using N,N-dicyclohexylcarbodiimide/1-hydroxybenzotriazole (DCC/HOBt) following Stewart and Young (supra). After each amino acid coupling, the peptide was acetylated using a mixture of acetic anhydride and diisopropylethylamine in N-methylpyrrolidone . The completed peptide was cleaved from the resin with simultaneous deprotection of the side chain protecting groups using anhydrous HF (25 mL) in the presence of anisole (2.5 mL) at -10°C for 30 minutes and at 0°C for 60 minutes. After evaporation of the HF in vacuo, the residue was washed with anhydrous ether, and the crude peptide extracted with 10% acetic acid.
Lyophilization of the 10% acetic acid extract gave 900 mgs of crude product. The peptide was purified by medium pressure ODS reversed phase column chromatography using a gradient of 22-45% CH3CN in 0.1% TFA. The product eluted in three fractions, which were concentrated and lyophilized to give 130 mgs of white solid of >98% purity.
Compound 1
AVSEHOLLHDKGRSIODLRRRELLEKLLEKLHTA-NH2 (SEQ ID NO: 7) Physical Data:
m.p. 150-159°C [α]D 25 -34.88° (c 0.16, H2O)
FAB (C175H300N56O51) : [M+H] + 4005.5
AAA: Asp, 1.9(2); Glu, 5.6(6); Ser, 1.6(2); His, 2.7(3); Gly, 1.0(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 2.8(3); Val, 1.0(1); Ile, 0.9(1); Leu, 7.3(8); Lys, 4.0(4) .
Similarly, Compounds 2, 5-18, and 21-70 were prepared and
characterized, substituting PAM resin as needed for the synthesis of hydroxy-terminal polypeptides. Compound 2
AVSEHOLLHDKGKSIODLRRRELLEKLLEKLHTA-OH (SEQ ID NO: 6) Physical Data:
m.p. 154-170°C [α]D 25 -49.35° (c 0.46, H2O)
FAB (C175H301N57O50) : [M+H] + 4005.0
AAA: Asp, 2.1(2); Glu, 5.9(6); Ser, 1.7(2); His, 2.9(3); Gly 1.1(1); Thr,
1.0(1); Ala, 1.9(2); Arg, 3.0(3); Val, 1.2(1); Ile, 1.0(1); Leu,
7.8(8); Lys, 4.2(4) .
Compound 5
AVSEHOLLHDKGKSIODLRRRELLERLLERLHTA-OH (SEQ ID NO: 15) Physical Data:
m.p. 147-165°C [α]D 25 -49.17° (c 0.66, H2O)
FAB (C175H299N59O52) : [M+H] +4061
AAA: Asp, 2.1(2); Gly, 6.1(6); Ser, 1.8(2); His, 3.1(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 5.0(5); Val, 1.0(1); Ile, 0.9(1); Leu, 7.7(8); Lys, 1.9(2) .
Compound 6
AVSEHOLLHDRGRSIODLRRRELLERLLERLHTA-OH (SEQ ID NO: 16)
Physical Data:
m.p. 150-170°C [α]D 25 -48.65° (c 0.54, H2O)
FAB (C175H299N63O52) : [M+H] + 4118.0
AAA: Asp, 2.1(2); Glu, 6.1(6); Ser, 1.8(2); His, 3.2(3); Gly, 1.2(1); Thr,
1.0(1); Ala, 2.0(2); Arg, 6.9(7); Val, 1.0(1); Ile, 1.0(1); Leu, 7.8(8) .
Compound 7
AVSEHOLLHDRGRSIODLRRRELLERLLKRLHTA-OH (SEQ ID NO: 17)
Physical Data:
m.p. 177-182°C [α]D 25 -46.17° (c 0.14, H2O)
FAB (C176H304N62O50) : [M+H] + 4117
AAA: Asp, 2.0(2); Glu, 4.8(5); Ser, 1.8(2); His, 3.2(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 6.7(7); Val, 1.0(1); Ile, 1.0(1); Lys,
7.7(8); Lys, 0.9(1) .
Compound 8
AVSEHOLLHDKGKSIODLRRRELLEKLLRKLHTA-OH (SEQ ID NO: 5) Physical Data:
m.p. 147-165°C [α],,25 -49.17° (c 0.66, H2O)
FAB (C176H305N59O49) : [M+H] + 4033.0
AAA: Asp, 2.0(2); Glu, 4.8(5); Ser, 1.8(2); His, 2.7(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 2.0(2); Arg, 3.9(4); Val, 1.0(1); Ile, 1.0(1); Leu, 7.9(8); Lys, 4.0(4) .
Compound 9
AVSEHOLLHDKGKSIODLRRRELLEKLLEKLHTAGRR-OH (SEQ ID NO: 10)
Physical Data:
m.p. 158-160°° [α]D 25 -44.76° (c 0.1, HjO)
FAB (C189H326N64O55): [M] + 4375.0
AAA: Asp, 2.0(2); Glu, 5.9(6); Ser, 1.7(2); His, 2.9(3); Gly, 2.3(2); Thr, 1.0(1); Ala, 1.9(2); Arg, 5.0(5); Val, 1.2(1); Ile, 1.0(1); Leu, 7.8(8); Lys, 4.3(4). .ompound 10
AVSEAQLLHDLGKSIODLRRRELLEKLLEKLHAL-OH (SEQ ID NO: 14) Physical Data:
m.p. 170-175°C [α]D 25 -31.59° (c 0.54, H2O)
FAB (C174H300N52O51) : [M+H] + 3936.0
AAA: Asp, 2.0(2); Glu, 6.0(6); Ser, 1.8(2); His, 2.0(2); Gly, 1.2(1); Ala, 3.0(3); Arg, 2.8(3); Val, 1.1(1); Ile, 1.0(1); Leu, 9.9(10); Lys, 3.0(3) .
Compound 11
AVSEHOLLHDKGKSIODLRRRELLEKLLELLKEL-NH2 (SEQ ID NO: 11) Physical Data:
m.p. 172-174°C [α]D 25 -43.29° (c 0.2, H.O)
FAB (C179H311N55O52) : [M+H] + 4065.8
AAA: Asp, 2.2(2); Glu, 7.7(7); Ser, 1.7(2); His, 2.0(2); Gly, 1.0(1); Ala,
1.0(1); Arg, 3.0(3); Val, 1.1(1); Ile, 1.0(1); Leu, 9.3(9); Lys, 5.1(5) .
Compound 12
AVSEIOFXHNLGKHLSSXERVELLEKLLEK_LHNY-NH2 (X=Nle , SEQ ID NO: 23)
Physical Data:
m.p. 178°C [α]D 25 -36.88° (c 0.4, BjO)
FAB (C182H295N50O51) : [M+H] + 4001.6
AAA: Asp, 2.1(2); Glu, 6.5(6); Ser, 2.7(3); His, 3.1(3); Gly, 1.1(1); Ala, 1.0(1); Arg, 1.0(1); Tyr, 0.8(1); Val, 2.0(2); Phe, 1.0(1); Ile,
0.9(1); Leu+Nle, 8.5(7+2); Lys, 3.1(3) .
Compound 13
AVSEIOFXHNLGKHLSSXRRRELLEKLLEKLHNY-NH2 (X=Nle . SEQ ID NO: 24)
Physical Data:
m.p. 260°C [α]D 25 -37.02° (c 0.2, H2O)
FAB (C184H304N56O49) : [M+H] + 4084
AAA: Asp, 2.1(2); Glu, 5.5(5); Ser, 2.6(3); His, 3.1(3); Ala, 1.0(1); Gly, 1.1(1); Arg, 3.2(3); Tyr, 1.0(1); Val, 1.0(1); Phe, 1.0(1); Ile, 1.0(1); Leu, 9.0(9); Lys, 3.0(3) .
Compound 14
AVSEHOLLHDKGKSIODLRRRALAEALAEALHTA-NH2 (SEQ ID NO: 20)
Physical Data:
m.p. 190-225°C [α]D 25 -56.58° (c 0.36, H2O)
FAB (C161H272N54O49) : [M+H] + 3747.0
AAA: Asp, 2.1(2); Glu, 4.9(5); Ser, 1.7(2); His, 2.6(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 7.6(7); Arg, 2.8(3); Val, 1.2(1); Ile, 1.0(1); Leu, 6.6(6) ; Lys, 1.9(2) .
Compound 15
AVSEHOLLHDKGKSIODLARRELLEKLLEKLHTA-NH2 (SEQ ID NO: 12)
Physical Data:
m.p. 170-180°C [α]D 25 -48.19° (c 0.2, Hp)
FAB (C172H293N53O51) : [M+H] + 3919.0
AAA: Asp, 2.1(2); Glu, 6.1(6); Ser, 1.7(2); His, 3.1(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 3.0(3); Arg, 2.1(2); Val, 1.1(1); Ile, 1.0(1); Leu, 8.0(8) ; Lys, 4.4(4) . Compound 16
AVSEHOLLHDKGKSIQDLRRAELLEKLLEKLHTA-NH2 (SEQ ID NO: 13)
Physical Data:
m.p. 190-195°C [α]D 25 -50.50° (c 0.4, H2O)
FAB (C172H293N53O51) : [M+H] + 3919.0
AAA: Asp, 2.1(2); Glu, 6.0(6); Ser, 1.8(2); His, 3.1(3); Gly, 1.1(1); Thr,
1.0(1); Ala, 3.0(3); Arg, 2.1(2); Val, 1.1(1); Ile, 1.0(1); Leu,
7.5(8) ; Lys, 4.2(4) .
Compound 17
AVSEHOLLHDKGKSIODLRRRSLLSSLLSSLHTA-NH2 (SEQ ID NO: 21)
Physical Data:
m.p. 195-204°C [α]D 25 -67.11° (c 0.3, H2O)
FAB (C163H280N54O50) : [M+H] + 3796.0
AAA: Asp, 2.1(2); Glu, 2.9(3); Ser, 6.8(7); His, 3.1(3); Gly, 1.2(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.0(3); Val, 1.0(1); Ile, 1.0(1); Leu, 8.2(8) ; Lys, 2.0(2) .
Compound 18
AVSEHOLLHDKGKSIODLRRRAFYDKVAEKLHTA-NH2 (SEQ ID NO: 22) Physical Data:
m.p. 200-207°C [α]D 25 -60.26° (c 0.6, H2O)
FAB (C174H284N56O50) : [M+H] + 3960.0
AAA: Asp, 2.9(3) , Glu, 3.5(4); Ser, 1.4(2); His, 2.6(3); Gly, 0.9(1); Thr,
1.0(1); Ala, 4.0(4); Arg, 3.0(3); Tyr, 0.9(1); Val, 1.9(2); Phe,
1.1(1); Ile, 0.9(1); Leu, 3.6(4); Lys, 4.1(4) . Compound 21
AVSEIOFLHN LGKHLSSLRR RELLEKLLEK LHNY-NH2 (SEQ ID NO: 35) Physical Data:
m.p. 148-155°C [α]D 25 -45.97 (c 0.26, H2O)
FAB (C184H304N56O49) = [M+H] + 4084
AAA: Asx, 2.1(2); Glx, 5.0(5); Ser, 2.7(3); His, 3.0(3); Gly, 1.0(1); Ala,
0.9(1); Arg, 3.1(3); Tyr, 0.9(1); Val, 1.0(1); Phe, 0.9(1); Ile, 0.9(1); Leu 9.3(9); Lys, 3.2(3) .
Compound 22
AVSEIOFLHN LGKHLSSLRR RELLEKLLEK LHNX-NH2 (SEQ ID NO: 36)
(X = homoserine)
Physical Data:
m.p. 69.4-128°C [α]„" -43.93 (c 0.15, H2O)
FAB (C179H302N56O49) : [M+H] + 4022.9
AAA: Asx, 2.0(2); Glx, 4.9(5); Ser, 2.6(3); His, 2.8(3); Gly, 1.0(1); Ala, 1.0(1); Arg, 3.0(3); Val, 1.0(1); Phe, 1.0(1); Ile, 0.9(1); Leu, 8.8(9) ; Lys, 3.4(3) ;
Compound 23
AVSEIOFLHN KGKHLSSLRR RELLEKLLEK LHNX-NH2 (SEQ ID NO: 37)
(X = homoεerine)
Physical Data:
m.p. 87.1-142.1°C [α]D 25 -52.14 (c 0.41, H2O)
FAB (C179H303N57O49) : [M+H] + 4038
AAA: Asx, 2.1(2); Glx, 4.9(5); Ser, 2.7(3); His, 2.8(3); Gly, 1.0(1);
hSer, 1.0(1); Ala, 1.0(1); Arg, 3.0(3); Val, 1.1(1); Phe, 0.9(1); Ile, 0.9(1); Leu, 7.9(8); Lys, 3.7(4) . Compound 24
AVSEHOLLHD KGKSIODLKL RELLEKLLEK LHTA-NH2 (SEQ ID NO: 38) Physical Data:
m.p. 175-182°C [α]D 25 -49.99 (c 0.47, H2O)
FAB (C175H299N49O51) : [M+H]+ 3906.5
AAA: Asx, 2.1(2); Glx, 6.5(6); Ser, 1.8(2); His, 3.1(3); Gly, 1.1(1); Thr,
1.0(1); Ala, 2.1(2); Val, 1.1(1); Ile, 1.0(1); Leu, 9.1(9); Lys,
6.5(6) .
Compound 25
AVSEHOLLHD KGKSIODLRR RELLERLLER LHTA-NH2 (SEQ ID NO: 39) Physical Data:
m.p. 136.5-153.5°C [α]D 25 -32.57 (c 0.13, H2O)
FAB (C175H300N60O51) : [M+H]+ 4060.8
AAA: Asx, 2.2(2); Glx, 6.2(6); Ser, 1.8(2); His, 3.2(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.1(2); Arg, 5.2(5); Val, 1.1(1); Ile, 1.1(1); Leu, 8.4(8) ; Lys, 2.2(2) .
Compound 26
AVSEHOLLHD KGKSIODLRR RELLERLLER LHTAP-OH (SEQ ID NO:40) Physical Data:
m.p. 125.8-127.2°C [α]D 25 -54.62 (C 0.23, H2O)
FAB (C180H306N60O53) : [M+H] + 4158.0
AAA: Asx, 2.1(2); Glx, 6.2(6); Ser, 1.8(2); His, 2.9(3); Gly, 1.1(1); Thr,
1.0(1); Ala, 2.0(2); Arg, 5.1(5); Val, 1.0(1); Ile, 1.0(1); Leu,
8.0(8); Lys, 2.1(2); Pro, 1.1(1) .
Compound 27
AVSEHOLLHD KGKSIODLRR RELLERLLER LHTAGRR-OH (SEQ ID NO: 41) Physical Data:
m.p. 106-137.3°C [α]D 25 -39.55 (c 0.67, H2O)
FAB (C189H326N68O55) : [M+H] + 4430.5
AAA: Asx, 2.1(2); Glx, 5.9(6); Ser, 1.6(2); His, 2.7(3); Gly, 2.2(2); Thr, 1.0(1); Ala, 1.8(2); Arg, 7.3(7); Val, 0.8(1); Ile, 1.0(1); Leu, 8.1(8) ; Lys, 2.1(2) .
Compound 28
AVSEHOLLHD KGKSIODLRR RELLERLLER LHTAGRRX-NH2 (SEQ ID NO:42)
(X = homoserine)
Physical Data:
m.p. 80°C [α]D 25 -48.64 (c 0.09, H2O)
FAB (C193H334N70O56) : [M+H] + 4530.0
AAA: Asx, 2.2(2); Glx, 6.1(6); Ser, 1.7(2); His, 3.0(3); Gly, 1.9(2);
hSer, 1.0(1); Thr, 1.0(1); Ala, 2.1(2); Arg, 7.2(7); Val, 0.8(1); Ile, 1.0(1); Leu, 8.4(8); Lys, 2.1(2).
Compound 29
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTY-NH2 (SEQ ID NO:43)
Physical Data:
m.p. 160-172°C [α]D 25 -49.85 (c 0.34, H2O)
FAB (C181H304N56O52) : [M+H] + 4096.9
AAA: Asx, 2.0(2); Glx, 5.6(6); Ser, 1.7(2); His, 3.1(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 0.9(1); Arg, 3.0(3); Tyr, 0.9(1); Val, 1.0(1); Ile,
1.0(1); Leu, 7.7(8); Lys, 4.4(4) . Compound 30
AVSEHOLLHD KGYSIODLRR RELLEKLLEK LHTA-NH2 (SEQ ID NO: 44)
Physical Data:
m.p. 130-171°C [α]D 25 -40.65 (c 0.34, H2O)
FAB (C178H297N55O52) : [M+H] + 4039.4
AAA: Asx, 2.0(2); Glx, 5.5(6); Ser, 1.8(2); His, 3.4(3); Gly, 1.1(1); Thr,
1.0(1); Ala, 2.0(2); Arg, 2.9(3); Tyr, 0.8(1); Val, 1.0(1); Ile,
0.9(1); Leu, 7.9(8); Lys, 3.4(3) .
Compound 31
AVSEHOLLHD KGCSIODLRR RELLEKLLEK LHTA-NH2 (SEQ ID NO: 45)
Physical Data:
m.p. 140-160°C [α]D 25 -44.48 (c 0.25, H2O)
FAB(C172H293N55O51S1) : [M+H] + 3979
AAA: Asx+Cys, 3.0(2+1); Glx, 5.6(6); Ser, 1.7(2); His, 3.0(3); Gly,
1.0(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 2.5(3); Val, 1.0(1); Ile, 0.9(1); Leu, 7.5(8); Lys, 3.3(3).
Compound 32
AVSEHOLLHD KGXSIODLRR RELLEKLLEK LHTA-NH2 (SEQ ID NO:46)
(X = Cys(CH2CONH(CH2)2NH(biotinyl)))
Physical Data:
m.p. (not determined) [α]D 25 (not determined)
FAB (C186H316N59O54S2) : [M+H] + 4306.6
AAA: Asx, 2.2(2); Glx, 6.1(6); Ser, 1.8(2); His, 3.8(3); Gly, 1.0(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.1(3); Val, 1.1(1); Ile, 0.9(1); Leu, 8.3(3); Lys, 3.3(3). Compound 33
AVSEHOLLHD KGXSIODLRR RELLEKLLEK LHTA-NH2 (SEQ ID NO:47) (X = Lys(7-dimethylamino-2-oxo-2H-1-benxopyran-4-acetyl))
Physical Data:
m.p. 135-205°C [α]D 25 -26.92 (c 0.104, 50% aq.
HOAc)
FAB (C188H311N57O54) : [M+H] + 4233
AAA: Asx, 1.9(2); Glx, 6.3(6); Ser, 1.7(2); His, 3.2(3); Gly, 1.0(1); Thr, 1.1(1); Ala, 2.0(2); Arg, 3.2(3); Val, 1.1(1); Ile, 0.9(1); Leu, 8.2(8); Lys, 4.5(4).
Compound 34
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTAG-OH (SEQ ID NO:48)
Physical Data:
m.p. 92.1-146.6°C [α]D 25 -40.76 (c 0.34, H2O)
FAB (C177H302N56O53) : [M+H] + 4062.0
AAA: Asx, 2.0(2); Glx, 5.7(6); Ser, 1.8(2); His, 3.0(3); Gly, 2.2(2); Thr, 0.9(1); Ala, 1.9(2); Arg, 2.8(3); Val, 1.2(1); Ile, 0.9(1); Leu,
7.5(8) ; Lys, 4.2(4) . Compound 35
AVSXHOLLHZ KGKSIOZLRR RXLLXKLLXK LHA-OH (SEQ ID NO: 49)
(X = Glu (OCH3); Z = Asp (OCH3))
Physical Data:
m.p. (not determined) [α]D 25 -21.96 (c 0.132, H2O)
FAB (C181H311N55O52) : [M+H] + 4089.0
AAA: Asx, 2.1(2); Glx, 6.3(6); Ser, 1.8(2); His, 3.3(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.1(3); Val, 1.1(1); Ile, 0.9(1); Leu, 8.0(8); Lys, 4.2(4) .
Compound 36
AVSXHOLLHZ KGKSIOZLRR RXLLXKLLXK LHA-OCH3 (SEQ ID NO: 50)
(X = Glu (OCH3); Z = ASP (OCH3))
Physical Data:
m.p. (not determined) [α]D 25 -46.80 (c 0.07, H2O)
FAB (C182H313N55O52) : [M+H] + 4103
AAA: Asx, 2.1(2); Glx, 6.2(6); Ser, 1.4(2); His, 3.0(3); Gly, 1.1(1); Thr, 1.1(1); Ala, 1.7(2); Arg, 3.2(3); Val, 0.6(1); Ile, 0.9(1); Leu, 8.0(8); Lys, 4.1(4). Compound 37
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTX-OH (SEQ ID NO: 51)
(X = homoserine)
Physical Data:
m.p. (not determined) [α]D 25 (not determined)
FAB (C176H301N55O53) : [M+H] + 4035.1
AAA: Asx, 2.1(2); Glx, 5.9(6); Ser, 2.0(2); His, 3.1(3); Gly, 0.8(1);
hSer, 0.8(1); Thr, 1.0(1); Ala, 1.0(1); Arg, 3.0(3); Val, 1.3(1); Ile, 1.0(1); Leu, 8.1(8); Lys, 3.8(4).
Compound 38
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTAP-OH (SEQ ID NO:52) Physical Data:
m.p. 152.1-186.5°C [α]D 25 -55.91 (c 0.33, H2O)
FAB (C180H3o6N3p33) : [M+H] + 4102.6
AAA: Asx, 2.0(2); Glx, 5.6(6); Ser, 1.7(2); His, 2.9(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 2.9(3); Val, 1.2(1); Ile, 1.0(1); Leu, 7.7(8); Lys, 4.3(4) .
Compound 39
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTP-OH (SEQ ID NO: 53)
Physical Data:
m.p. 120-148.2°C [α]D 25 -52.78 (c 0.47, Hp)
FAB (C177H301N55O52) : [M+H] + 4031.0
AAA: Asx, 2.0(2); Glx, 5.5(6); Ser, 1.8(2); His, 2.9(3); Gly, 1.0(1); Thr, 1.0(1); Ala, 0.9(1); Arg, 2.9(3); Val, 1.2(1); Ile, 0.9(1); Leu,
7.5(8); Lys, 3.6(3); Pro, 0.9(1).
Compound 40
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTP-NH2 (SEQ ID NO:54)
Physical Data:
m.p. 133.9-155.1°C [α]D 25 -54.22 (c 0.37, Hp)
FAB (C177H302N56O51) : [M+H] + 4030.7
AAA: Asx, 2.0(2); Glx, 5.6(6); Ser, 1.9(2); His, 2.9(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 0.9(1); Arg, 2.8(3); Val, 1.2(1); Ile, 1.1(1); Leu,
7.8(8); Lys, 4.2(4); Pro, 0.9(1) . Compound 41
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHP-NH2 (SEQ ID NO: 55)
Physical Data:
m.p. 142.8-166.1°C [α]D 25 -53.80 (c 0.38, H2O)
FAB (C175H299N49O51) : [M+H] + 3929
AAA: Asx, 2.0(2); Glx, 5.7(6); Ser, 1.8(2); His, 3.0(3); Gly, 1.1(1); Ala,
0.9(1); Arg, 2.8(3); Val, 1.2(1); Ile, 0.9(1); Leu, 7.4(8); Lys,
4.4(4); Pro, 0.9(1) .
Compound 42
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LP-NH2 (SEQ ID NO: 56) Physical Data:
m.p. 161.0-177.0°C [α]D 25 -61.97 (c 0.19, H2O)
FAB (C175H299N49O51) : [M+H] + 3792.0
AAA: Asx, 2.2(2); Glx, 5.9(6); Ser, 1.9(2); His, 2.1(2); Gly, 1.1(1); Ala, 1.0(1); Arg, 3.0(3); Val, 1.1(1); Ile, 1.0(1); Leu, 7.9(8); Lys, 4.3(4); Pro, 0.9(1).
Compound 43
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTRSAW-OH (SEQ ID NO: 57)
Physical Data:
m.p. 181-202°C [a] D-~ -45.14 (c 0.19, H2O)
FAB (C195H326N62O56): [M+H] + 4435.2
AAA: Asx, 2.0(2); Glx, 5.8(6); Ser, 2.8(3); His, 2.8(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 3.7(4); Ile, 0.9(1); Leu, 7.5(8); Lys,
4.3(4); Trp, 0.9(1).
Compound 44
AVSEHOLLHD RGRSIODLRR RELLERLLER LHTAGRRTRSAW-OH (SEQ ID NO:58)
Physical Data:
m.p. 130-132.2°C [α]D 25 -46.66 (c 0.195, Hp)
FAB ( C216H365N8p62) : [M+H] + 5088.8
AAA: Asx, 2.2(2); Glx, 6.0(6); Ser, 2.7(3); His, 3.0(3); Gly, 2.2(2); Thr,
2.1(2); Ala, 3.0(3); Arg, 10.5(10); Val, 0.9(1); Ile, 1.0(1); Leu,
8.2(8); Trp, 1.0(1) . Compound 45
AVSEHOLLHD RGRSIODLRR RELLERLLER LHTAGRRTRSAW-NH2 (SEQ ID NO: 59)
Physical Data:
m.p. 158-174°C [α]D 25 -43.57 (c 0.53, Hp)
FAB ( C216H366N82O61) : [M+H]+ 5087.4
AAA: Asx, 1.9(2); Glx, 5.6(6); Ser, 2.6(3); His, 3.3(3); Gly, 2.1(2); Thr,
2.0(2); Ala, 2.9(3); Arg, 10.1(10); Val, 0.9(1); Ile, 1.0(1); Leu,
8.3(8); Trp 1.1(1).
Compound 46
AVSEHOLLHD RGXSIODLRR RELLERLLER LHTAGRRTRSAW-OH (SEQ ID NO: 60)
(X = Lys (dihydrocinnamoyl))
Physical Data:
m.p. 165.4-175.2°C [α]D 25 -40.43 (c 0.20, Hp)
FAB (C225H374N80O62) : [M+H] + 5191
AAA: Asx, 2.1(2) , Glx, 6.3(6); Ser, 2.8(3); His, 3.2(3); Gly, 2.1(2) , Thr, 2.0(2); Ala, 3.2(3); Arg, 9.9(9); Val, 1.0(1) , Ile, 0.9(1); Leu, 8.6(8); Lys, 1.1(1); Trp, 1.1(1) . Compound 47
AVSEIOFXHN LGKHLSSXTR SAWLRKKLOD VHNY-NH2 (SEQ ID NO: 61)
(X = norleucine)
Physical Data:
m.p. 140-160°C [α]D 25 -56.88 (c 0.16, H2O)
FAB (C180H287N55O58) : [M+H] + 3989.8
AAA: Asx, 3.0(3); Glx, 2.9(3); Ser, 3.7(4); His, 2.8(3); Gly, 1.1(1); Thr, 0.9(1); Ala, 1.9(2); Arg, 2.0(2); Tyr, 1.0(1); Val, 1.7(2); Phe, 0.9(1); Ile, 0.9(1); Leu+Nle 5.8(2+4); Lys, 3.4(3); Trp, 1.1(1).
Compound 48
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTMA-NH2 (SEQ ID NO: 62)
Physical Data:
m.p. 140-210°C [α]D 25 -47.75 (c 0.178, H2O)
FAB (C180H309N57O52S1) : [M+H] + 4135.0
AAA: Asx, 2.3(2); Glx, 6.6(6); Ser, 1.4(2); His, 3.2(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.1(3); Val, 0.9(1); Met, 1.1(1); Ile,
1.0(1); Leu, 8.8(8); Lys, 4.4(4) .
Compound 49
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTX (SEQ ID NO: 63)
(X = 1,4-diaminobutyryl lactam)
Physical Data:
m.p. 161-181°C [α]D 25 -48.38 (c 0.25, H2O)
FAB(C176H300N56O51) : [M+H] + 4016.8
AAA: Asx, 2.1(2); Glx, 6.3(6); Ser, 1.7(2); His, 3.3(3); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.1(2); Arg, 2.9(3); Val, 0.9(1); Ile, 0.9(1); Leu, 8.0(8); Lys, 3.8(4) .
Compound 50
AVSEHOLLHD KGKSIODLRR RFFLEKLLEK LHTA-NH2 (SEQ ID NO: 64) Physical Data:
m.p. 136.5-156.8°C [α]D 25 -49.89 (c 0.24, Hp)
FAB (C182H300N56O49) : [M+H] + 4056.0
AAA: Asx, 2.2(2); Glx, 5.0(5); Ser, 1.9(2); His, 3.3(3); Gly, 1.0(1); Thr,
1.0(1); Ala, 2.1(2); Arg, 3.1(3); Val, 1.0(1); Phe, 2.0(2); Ile,
0.9(1); Leu, 7.2(7); Lys, 3.5(4).
Compound 51
AVSEHOLLHD KGKSIODLRR RELLHKLLEK LHTA-NH2 (SEQ ID NO: 65)
Physical Data:
m.p. 80.7-141.0°C [α]D 25 -55.38 (c 0.23, Hp)
FAB (C176H300N58O49) : [M+H] + 4012.8
AAA: Asx, 2.2(2); Glx, 4.9(5); Ser, 1.8(2); His, 4.3(4); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.1(3); Val, 1.1(1); Ile, 1.0(1); Leu, 8.1(8); Lys, 3.9(4).
Compound 52
AVSEHOLLHD KGKSIODLRR RELLEHLLEK LHTA-NH2 (SEQ ID NO: 66)
Physical Data:
m.p. 134.3-157.9°C [α]D 25 -50.72 (c 0.45, Hp)
FAB (C175H295N57O51) : [M+H] + 4012.8
AAA: Asx, 2.1(2); Glx, 5.9(6); Ser, 1.8(2); His, 4.2(4); Gly, 1.1(1); Thr, 1.0(1); Ala, 2.0(2); Arg, 3.0(3); Val, 1.1(1); Ile, 0.9(1); Leu,
8.1(8); Lys, 3.1(3) . Compound 53
AVSEHOLLHD KGKSIODLRR RELLEKLIAK LHTA-NH2 (SEQ ID NO: 67)
Physical Data:
m.p. 142.7-159.8°C [α]D 25 -54.01 (c 0.21, H2O)
FAB (C173H298N56O49) : [M+H] + 3946.0
AAA: Asx, 2.2(2); Glx, 4.9(5); Ser, 1.8(2); His, 3.1(3); Gly, 1.1(1); Thr,
1.0(1); Ala, 3.1(3); Arg, 3.1(3); Val, 1.0(1); Ile, 1.9(2); Leu,
7.0(7); Lys, 4.3(4).
Compound 54
AVSEHOLLHD KGKSIODLRR RELLEKLLEE IHTA-NH2 (SEQ ID NO: 68) Physical Data:
m.p. 138-185°C [α]D 25 -50.17 (c 0.14, H2O)
FAB(C174H295N55O53) : [M+H] + 4005
AAA: Asx, 2.2(2); Glx, 7.1(7); Ser, 1.7(2); His, 2.8(3); Gly, 1.0(1); Thr, 1.0(1); Ala, 2.1(2); Arg, 3.1(3); Val, 1.1(1); Ile, 1.7(2); Leu, 7.1(7); Lys, 2.7(3).
Compound 55
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTX-NHCH2CH3 (SEQ ID NO: 69)
(X = homoserine)
Physical Data
m.p. (not determined) [α]D 25 (not determined)
FAB (C178H306N56O52) : [M+H] + 4063.0
AAA: Asx, 2.1(2); Glx, 5.8(6); Ser, 1.7(2); His, 3.1(3); Gly, 0.9(1);
Thr, 1.0(1); Ala, 0.9(1); Arg, 3.0(3); Val, 1.1(1); Ile, 1.0(1); Leu, 8.4(8); Lys, 3.7(4); hSer, 0.9(1). Compound 56
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTX-NHCH2CH2C6H2 (SEQ ID NO: 70)
(X = homoserine)
Physical Data
m.p. (not determined) [α]D 25 (not determined)
FAB (C184H310N56O52) : [M+H] + 4138.8
AAA: Asx, 2.0(2); Glx, 5.9(6); Ser, 1.7(2); His, 2.9(3); Gly, 0.9(1);
Thr, 1.0(1); Ala, 0.9(1); Arg, 3.0(3); Val, 1.0(1); Ile, 0.9(1); Leu, 8.0(8); Lys, 4.1(4); hSer, 0.9(1).
Compound 57
I l
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTA-NH2 (SEQ ID NO: 71)
Physical Data
m.p. 142.5-163.5°C [a]^ -34.31 (c 0.17, Hp)
FAB (C175H298N56O50) : [M+H] + 3986.4
AAA: Asx, 1.9(2); Glx, 5.9(6); Ser, 1.8(2); His, 3.2(3); Gly, 1.1(1); Ala, 2.0(2); Arg, 3.0(3); Thr, 1.0(1); Val, 1.1(1); Ile, 0.9(1); Leu,
8.0(8); Lys, 4.0(4).
Compound 58
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTRSAW-NH2 (SEQ ID NO:72)
Physical Data
m.p. 158-163°C [α]D 25 -46.06 (c 0.17, H2O)
FAB (C195H327N63O55) : [M+H] + 4434.8
AAA: Asx, 2.0(2); Glx, 5.5(6); Ser, 2.7(3); His, 3.1(3); Gly, 1.0(1); Ala, 1.8(2); Arg, 4.0(4); Thr, 0.9(1); Val, 0.9(1); Ile, 0.9(1); Leu,
7.5(8); Lys, 3.9(4); Trp, 1.0(1) . Compound 59
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTRSAX-OH (SEQ ID NO: 73)
(X = Nal (2) = 3-(2-naphthyl)-L-alanine)
Physical Data
m.p. 156-162°C [α]D 25 -44.44 (c 0.189, Hp)
FAB (C197H328N62O55) : [M+H] + 4445.6
AAA: Asx, 2.1(2); Glx, 5.5(6); Ser, 2.8(3); His, 2.9(3); Gly, 1.0(1); Ala, 2.0(2); Arg, 4.0(4); Thr, 0.9(1); Val, 1.0(1); Ile, 0.9(1); Leu, 7.5(8); Lys, 4.2(4); Nai, 1.1(1).
Compound 60
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTASAW-OH (SEQ ID NO: 74)
Physical Data
m.p. 159-164°C [α]D 25 -50.94 (c 0.29, Hp)
FAB (C192H320N60O55) : [M+H] + 4349.0
AAA: Asx, 2.0(2); Glx, 5.6(6); Ser, 2.7(3); His, 3.2(3); Gly, 1.0(1); Ala, 3.1(3); Arg, 2.8(3); Thr, 1.0(1); Val, 1.1(1); Ile, 0.9(1); Leu,
7.6(8); Lys, 4.0(4); Trp, 1.0(1) .
Compound 61
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTAEIRA-OH (SEQ ID NO: 75) Physical Data
m.p. 155-210°C [α]D 25 -46.15 (c 0.12, H2O)
FAB (C195H334N62O58) : [M+H] + 4475.8
AAA: Asx, 2.2(2); Glx, 6.9(7); Ser, 1.7(2); His, 3.2(3); Gly, 1.1(1); Ala,
3.1(3); Arg, 4.0(4); Thr, 0.9(1); Val, 1.1(1); Ile, 1.9(2); Leu, 8.1(8); Lys, 4.1(4) . Compound 62
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTAEIR-OH (SEQ ID NO: 76) Physical Data
m.p. 186-218°C [α]D 25 -52.73 (c 0.265, H2O)
FAB(C192H329N61O57) : [M+H] + 4404.4
AAA: Asx, 2.0(2); Glx, 6.6(7); Ser, 1.9(2); His, 3.4(3); Gly, 1.1(1); Ala, 2.0(2); Arg, 3.8(4); Thr, 1.0(1); Val, 1.1(1); Ile, 1.7(2); Leu,
7.9(8); Lys, 4.0(4)
Compound 63
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTAEI-OH (SEQ ID NO: 77) Physical Data
m.p. 169-205°C [α]D 25 -50.78 (c 0.51, Hp)
FAB (C186H317N57O56) : [M+H] + 4248.0
AAA: Asx, 2.2(2); Glx, 6.8(7); Ser, 1.8(2); His, 3.3(3); Gly, 1.0(1); Ala, 2.0(2); Arg, 3.0(3); Thr, 1.0(1); Val, 1.0(1); Ile, 1.8(2); Leu,
7.8(8); Lys, 3.6(4) .
Compound 64
AVSEHOLLHD KGKSIODLRR RELLEKLLEK LHTAE-OH (SEQ ID NO: 78)
Physical Data
m.p. 199-205°C [α]D 25 -52.47 (c 0.41, Hp)
FAB (C180H306N56O55) : [M+H] + 4135.0
AAA: Asx, 2.0(2); Glx, 6.6(7); Ser, 1.9(2); His, 3.3(3); Gly, 1.1(1); Ala, 2.0(2); Arg, 2.9(3); Thr, 1.0(1); Val, 1.1(1); Ile, 1.0(1); Leu, 8.2(8); Lys, 3.8(4) . Compound 65
AVSEIOFX.HN KGKHLSSX1ER VEWLRKKLOD VHNX2 (SEQ ID NO: 79) (X1 = L-norleucine; X2 = homoserine lactone) Physical Data
m.p. 166-176°C [α]D 25 -52.22 (c 0.25, H2O)
FAB (C180H288N54O50) : [M+H] + 4008.6
AAA: Asx, 3.1(3); Glx, 4.8(5); Ser, 2.9(3); His, 2.9(3); Gly, 1.1(1); Ala, 1.1(1); Arg, 2.0(2); Val, 2.7(3); Phe, 1.0(1); Ile, 1.0(1); Leu + Nle 5.9 (4 + 2); Lys, 2.8(3) .
Compound 66
SEHOLLHD KGKSIODLRR RELLEKLLEK LHTA-NH2 (SEQ ID NO: 80)
Physical Data:
m.p. 134.2°C [α]D 25 -48.12 (c 0.36, H2O)
FAB (C167H286N54O49) : [M+H] + 3834.4
AAA: Asx, 2.0(2); Glx, 5.7(6); Ser, 1.7(2); His, 2.9(3); Gly, 1.0(1); Thr, 0.9(1); Ala, 1.0(1); Arg, 2.8(3); Ile, 0.9(1); Leu, 7.4(8); Lys,
4.3(4) .
Compound 67
LLHD KGKSIODLRR RELLEKLLEK LHTA-NH2 (SEQ ID NO: 81)
Physical Data:
m.p. 128.5-184.5°C [α]D 25 -6.53 (c 0.69, MeOH)
FAB (C148H259N47O41) : [M+H] + 3353
AAA: Asx, 2.0(2); Glx, 4.1(4); Ser, 0.9(1); His, 2.1(2); Gly, 1.0(1); Thr,
0.9(1); Ala, 1.0(1); Arg, 3.0(3); Ile, 1.0(1); Leu, 8.1(8); Lys, 4.2(4) . Compound 68
LHP KGKSIODLRR RELLEKLLEK LHTA-NH2 (SEQ ID NO: 82) Physical Data:
m.p. 165-210°C [α]D 25 -36.05(c 0.12, H2O)
FAB(C142H248N46O40) : [M+H] + 3239.0
AAA: Asx, 2.0(2); Glx, 3.9(4); Ser, 0.9(1); His, 1.9(2); Gly, 1.0(1); Thr, 1.0(1); Ala, 1.0(1); Arg, 2.9(3); Ile, 0.9(1); Leu, 6.8(7); Lys, 4.2(4) .
Compound 69
SEHOLLHD RGRSIODLRR RELLERLLER LHAGRRTRSAW-OH (SEQ ID NO: 83)
Physical Data:
m.p. 150-210°C [α]D 25 -18.0 (c 0.64, H2O)
FAB (C208H351N79O60): [M+H] + 4918.6
AAA: Asx, 2.2(2); Glx, 6.2(6); Ser, 2.8(3); His, 3.1(3); Gly, 2.2(2); Thr, 2.2(2); Ala, 2.2(2); Arg, 10.4(10); Ile, 1.0(1); Leu, 8.0(8); Trp, 1.1(1).
Compound 70
LLHD RGRSIODLRR RELLERLLER LHAGRRTRSAW-OH (SEQ ID NO: 84)
Physical Data:
m.p. 150-210°C [α]D 25 -41.70 (c 0.36, Hp)
FAB (C189H324N72O52) : [M+H] + 4437.14
AAA: Asx, 2.1(2); Glx, 4.1(4); Ser, 1.9(2); His, 2.0(2); Gly, 2.1(2); Thr, 2.0(2); Ala, 2.1(2); Arg, 9.7(10); Ile, 0.9(1); Leu, 7.4(8) . EXAMPLE II
[Met34, Ala35] Compound 1, AVSEHQLLHDKGKSIQDLRRRELLEK-LLEKLHTMA-NH2, (SEQ ID NO:25) , was prepared and purified following the procedures of
Example I. This polypeptide was converted to the homoserine lactone as follows. The purified peptide (160 mgs) was dissolved in 44% formic acid (4 mL) . This solution was combined with a premixed solution of cyanogen bromide (700 mgs) and phenol (1.6 mgs) in 44% formic acid (4 mL) at 0°C. The solution was stirred at 0°C for 2 hr and at room temperature for 2 hrs. The formation of the product was monitored by HPLC (Vydac® C-18, 300 A, 4.6 × 250 mm, flow of 1.2 mL/min, gradient 25-45% acetonitrile in 0.1% TFA over 10 min) . The reaction was complete within 4 hr. Half of the sample was concentrated and purified by preparative RP-HPLC (Vydac® C-18, gradient 25-45% acetonitrile in 0.1% TFA) . The homoserine lactone peptide fractions were pooled and lyophilized to give 28 mgs of white solid of >95% purity, Compound 4.
Compound 4
AVSEHOLLHDKGKSIODLRRRELLEKLLEKLHTX (X=hSerlac, SEQ ID NO: 9)
Physical Data:
m.p. 138-142°C [α] D 25 -50.66° (c 0.1, Hp)
FAB (C176H299N55O52) : [M+H] + 4017.61
AAA: Asp, 2.1(2); Glu, 6.1(6); Ser, 1.8(2); His, 3.0(3); Thi, 1.1(1); Ala, 1.1(1); Arg, 2.7(3); Val, 1.0(1); Ile, 1.0(1); Leu, 8.2(8); Lys,
3.8(4); Gly 1.09(1); hSer, 1.09(1).
EXAMPLE III
To prepare the homoserine amide, the crude hSerlactone analog.
Compound 4, was concentrated and treated with 25 mL saturated NH3 in methanol. The solution was stirred at 0°C for 2 hr and at room temperature for 16 hr. The reaction was monitored by HPLC (Vydac® C-18, 300 A, 4.6 × 250 mm, flow of 1.2 mL/min, gradient 20-45% acetonitrile in 0.1% TFA) and was complete within 18 hr. The solution was concentrated and purified by preparative RP-HPLC (Vydac® C-18, gradient of 25-45% acetonitrile in 0.1% TFA) . The homoserine amide peptide fractions were pooled and lyophilized to give 30 mgs of white solid of >98% purity. Compound 3.
Compound 3
AVSEHOLLHDKGKSIODLRRRELLEKLLEKLHTX-NH2 (X=hSer, SEQ ID NO: 8)
Physical Data:
m.p. 138-142°C [α] D 25 -45.97° (c 0.25, Hp)
FAB (C176H302N56O52) : [M+H] + 4033.9
AAA: Asp, 2.1(2); Glu, 6.1(6); Ser, 1.6(2); His, 2.8(3); Gly, 0.97(1); hSer, 0.97(1); Thi, 1.0(1); Ala, 1.0(1); Arg, 2.9(3); Val, 1.0(1); Ile, 1.0(1); Leu, 7.6(8); Lys, 3.9(4). EXAMPLE IV
Following Example I, the protected peptide-resin
BocAVS (Bzl) E (OBz) H (Bom) QLLHD (OBzl) R(Ts) GR (Ts) S (Bzl) IQD (OBz) - LR(Ts)R(Ts)E(OBz)LLE(OBzl)R(Ts)LLK(Fmoc)R(Ts)LH(Bom)T(Bzl)A- O-PAM was synthesized on a 0.35 mmol scale. All N" groups were protected with t-butoxycarbonyl (Boc); side chain protecting groups were as indicated.
After completion of the synthesis, the peptide resin was treated with 50 mL of 20% piperidine in dimethylformamide (DMF) at room temperature for 30 minutes to remove the fluorenylmethoxy-carbonyl (Fmoc) protecting group on lysine. The resin was washed successively with DMF, MeOH, CH2C12 and dried to give 1.6 g partially protected peptide. 0.8 g (0.175 mmol) of the partially protected peptide was acylated on lysine with 0.44 g (0.3 mmol) of methoxydi (ethyleneoxy) acetic acid [PEG (2) CH2COOH] in the presence of 0.16 g (0.3 mmol) benzotriazolyloxy-tris (pyrrolidino)phosphonium
hexafluorophosphate (PyBop) and 0.067 g (0.525 mmol) of diisopropylethyl amine (DIEA) in 20 mL DMF at room temperature for 5 hrs. After 5 hrs., the resin was filtered and washed successively with DMF, MeOH and CH2Cl2. The acylation step was repeated twice until negative ninhydrin result on the resin was obtained. The final peptide was cleaved from the resin with removal of the side chain protecting groups and purification as in
Example I; 100 mgs of Compound 19 were obtained.
Compound 19
AVSEHOLLHDRGRSIODLRRRELLERLLKRLHTA-OH (SEQ ID NO:18)
CH3O(CH2CH2O)2CH2C=O
Physical Data:
m.p. 145-195°C [α]D 25 -44.60° (c 0.2, Hp)
FAB (C183H316N64O54) : [M+H] + 4276.2
AAA: Asp, 2.1(2); Glu, 5.0(5); Ser, 1.6(2); His, 2.9(3); Gly, 0.9(1); Thr, 1.9(2); Arg, 7.1(7); Val, 1.1(1); Ile, 1.0(1); Leu, 8.0(8); Lys, 0.9(1) .
EXAMPLE V Peptide was synthesized, cleaved and purified in the same manner as in Example IV except 2-methoxypoly (ethylene-oxy) acetic acid
[PEG (5000) CH2CO2H] was used as the acylating agent. 0.8 g (0.175 mmol) of partially protected peptide yielded 300 mgs of pure Compound 20. Compound 20
AVSEHOLLHDRGRSIODLRRRELLERLLKRI-HTA-OH (SEQ ID NO: 19)
CH3O (CH2CH2O)110CH2C=O
Physical Data:
m.p. 105°C [α]D 25 -22.95° (c 0.11, 50% aq. HOAc)
AAA: Asp, 2.0(2); Glu, 4.8(5); Ser, 1.6(2); His, 2.6(3); Gly, 1.1(1); Thr, 1.1(1); Arg, 7.3(7); Val, 0.8(1); Ile, 0.9(1); Leu, 8.3(8); Lys, 1.1(1); Ala, 1.8(2).
EXAMPLE VI
Synthesis of hPTHrp (1-34) analog gene
A synthetic gene coding for the hPTHrp (1-34) analog Compound 4 (SEQ ID NO: 9) was designed having the nucleotide sequence and enzyme restriction sites shown in Figure 1. The requisite oligodeoxynucleotides were prepared with a DNA synthesizer (Milligen/Biosearch) using the phosphoramidite process of Sinha, et al., Nucleic Acid Research 12, 4539-4557 (1984).
After deprotection, the crude oligonucleotides were purified by gel electrophoresis on preparative 15% polyacrylamide gels. The
oligonucleotides were located with UV, excised from the gel, desalted over Waters cl8 Sep-pak® cartridges, and lyophilized.
Amplification via polymerase chain reaction (PCR) was carried out on a Perkin-Elmer Cetus thermal cycler, with 25 cycles of: 94°C for 1 minute, 50°C for 2 minutes, and 72°C for 3 minutes, using reagents, including Taq polymerase, from the "GeneAmp" DNA amplification kit (Perkin-Elmer Cetus).
Two overlapping oligonucleotides, an 88mer (2 μg), PTH3,
(SEQ ID NO:31) :
CCTCTAGATC TCCGCGGCGC TAGC ATG GCT GTT TCT GAA CAT CAG 45
Met Ala Val Ser Glu His Gln
1 5
CTG CTT CAT GAC AAA GGT AAA TCG ATT CAA GAT CTG AGA CGT C 88
Leu Leu His Asp Lys Gly Lys Ser Ile Gln Asp Leu Arg Arg
10 15 20
and an anti-sense 90mer (2 μg) , PTH4 (SEQ ID NO:32)
CCTCGAAGCT TATGCATCAT TATCTAGA CAT AGT ATG CAG CTT TTC 46
Met Thr His Leu Lys Glu
30
AAG CAG TTT CTC CAG CAG CTC GCG ACG TCT CAG ATC TTG AAT 88
Leu Leu Lys Glu Leu Leu Glu Arg Arg Arg Leu Asp Gln Ile
25 20 15
CG 90,
were prepared as the template DNA sequence for the hPTHrp
(1-34) analog gene. Utilizing the two flanking primers, PTHPCRl:
CCTCTAGATC TCCGCGGCGC TAG (SEQ ID NO: 33)
and PTHPCR2: CCTCGAAGCT TATGCATCAT TATC (SEQ ID NO: 34) , the entire gene was amplified by PCR. The amplified DNA products were purified by gel
electrophoresis on 4% NuSieve® agarose gel. The band containing the synthetic hPTHrp (1-34) analog gene, approximately 150 bases in length, was excised from the gel and approximately 200 ng of DNA isolated by Elu-Quik® glass gel DNA extraction (Schleicher & Schuell, Keene, NH) . EXAMPLE VII
Molecular Cloning of an hPTHrp (1-34) 1 Analog Gene To subclone the hPTHrp (1-34) analog gene of Example VI, 200 ng of the amplified DNA was isolated and cut by restriction enzymes HinD III and Sac II. As shown in Figure 2, the DNA was ligated to 2 μg TrpLE 18 Prot (Ile3, Pro5) plasmid previously cleaved with Hind III and Sac II.
The resulting plasmid, TrpLE 18 hPTHrp (1-34) 1, containing one copy of the hPTHrp (1-34) analog gene was then transformed into competent E. coli HB 101 cells (CLONTECH, Palo Alto, CA) . Transformants were subjected to PCR analysis to verify insertion. Transformed cell colonies were selected and boiled in 200 μL of water for 5 minutes; 2 μL were subjected to PCR with two primers flanking the insert. The PCR product was then analyzed on 1% agarose gel to confirm the presence of one copy of the hPTHrp (1-34) gene insert. TrpLE 18 hPTHrp (1-34) 1 construct was then verified by DNA sequencing on an automated DNA sequencer (Applied Biosystems Model 373A, Foster City, CA) using the vendor's Dye Deoxy Terminator Sequencing kit.
EXAMPLE VIII
Construction of a Trp LE 18 vector containing multiple
copies of the hPTHrp (1-34) analog gene
unique Nhe I and Xba I restriction sites are located near the beginning and end of the hPTHrp (1-34) analog gene sequence. These two sites, which recognize different sequences, but produce identical single strand cohesive termini, allow the construction of multiple copy
hPTHrp (1-34) genes within the Trp LE 18 vector.
The strategy for constructing repeated hPTHrp (1-34) sequences in tandem is outlined in Figure 3. In separate reactions, 5 μg of plasmid Trp LE 18 hPTHrp (1-34) 1 containing a single copy of the gene was cleaved with Bam HI + Nhe I and Xba I + Bam HI. From each digest, about 300 ng of the fragment containing the hPTHrp (1-34) analog gene was isolated. These two fragments were mixed and ligated to form the Trp LE 18 hPTHrp (1-34) 2 plasmid. This plasmid was used to transform competent E. coli HB 101 cells. Sizing of the transformed PCR products on 1% agarose gel was used to determine the presence of two copies of the hPTHrp (1-34) gene insert. TrpLE 18 hPTHrp (1-34) 2 containing two copies of the gene was then confirmed by DNA sequencing. The correct fusion of the two hPTHrp (1-34) genes results in the elimination of Nhe I and Xba I sites at the junction. This makes the remaining Xba I and Nhe I sites flanking the tandem genes unique.
By repeating this process the final plasmid Trp LE 18 hPTHrp (1-34) 4 containing four copies of the hPTHrp (1-34) gene was constructed, as shown in Figure 4. The sequence of Trp LE 18 hPTHrp (1-34)4 was found to be correct by DNA sequence analysis. EXAMPLE IX
Expression and Purification of Trp LE 18 hPTHrp (1-34)4
Induction of the Trp LE 18 hPTHrp (1-34)4.
A starter culture of 50 mL of LB culture media, J.H. Miller,
"Experiments in Molecular Genetics," p.431 (1972), incorporated herein by reference, containing 50μg/mL ampicillin and lOOμg/mL tryptophan, was inoculated with E. coli cells containing Trp LE 18 hPTHrp (1-34) 4 plasmid, and grown overnight at 37°C with vigorous shaking to an A550 of about 6. Two liters of LB culture media for production were pre-warmed to 37°C and seeded with 20 mL of the starter culture to give an A550 of about 0.06. The culture was then grown with vigorous shaking to an A550 of between 0.6 and 0.8, whereupon 2 mL of a 10 mg/mL solution of indole acrylic acid (IAA) was added. Growth was continued with good aeration for about 16 hr to a final A550 of about 6 (typically, between 4 and 10). The cells were concentrated by centrifugation and resuspended in 500 mL of 50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA buffer solution (Tris buffer).
The suspension was sonicated using a Heat Systems-Ultrasonics, Inc. model 220F sonicator (equipped with a 3/4" horn) operated at 50% of full capacity to avoid overheating.
To determine the extent of induction, the whole cells were analyzed by SDS-PAGE. The gene products derived from the TrpLE 18 hPTHrp (1-34)4 construct were seen as a major band of the predicted MW of approximately 17,000. This accounts for as much as 10% of the total cellular protein.
Isolation of the Fusion Protein.
The cell lysate was centrifuged for 15 min. at about 3600 x g to pellet the Trp LE 18 hPTHrp (1-34) 4 fusion protein; the supernatant was discarded. The pellet was resuspended in 200 mL Tris buffer, (typically 40-80 A550/mL).
EXAMPLE X
Processing of the Fusion Protein and Purification of homo-Serlactone hPTHrp (1-34) peptide
Cleavage of the methionine residues flanking the hPTHrp (1-34) multimeric fusion protein with CNBr releases the desired homo-Serlactone hPTHrp (1-34) polypeptide, which was purified as described below. CNBr Treatment of Fusion Protein.
The washed pellet of TrpLE 18 hPTHrp (1-34) 4 fusion protein was resuspended by gently stirring in 60 mL of 70% formic acid (about 20 mg/mL total protein; typically material from 1000 A550 units of cells is dissolved in 3 mL) . A few drops of octanol were added and N2 bubbled through the solution for 20 minutes before adding 5.5 g CNBr. This reaction was allowed to proceed for 6 hours at 25°C before an equal volume of 50:50 MeOH:Hp was mixed with the sample and subsequently removed by rotary evaporation. After 2 to 4 repetitions of this process, the bulk of the formic acid and CNBr were essentially removed. The sample was then evaporated to dryness, redissolved in 200 mL water and lyophilized for storage.
Purification of homo-Serlactone hPTHrp (1-34) .
The CNBr cleaved supernatant was dialyzed against 50 mM KH-PO4 pH 6.5 for 24 hours with multiple changes. During dialysis, pH was maintained at 6.5. After dialysis, the precipitates were removed by high speed
centrifugation. The supernatant was clarified through a Gelman 0.45μ filter device (Acrodisc 4184).
Cation Exchange Chromatography.
Initial purification was accomplished by cation exchange
chromatography on a Bio-Gel TSK-SP-5PW HPLC column (21.5 × 150mm).
Chromatographic conditions for a flow rate of 8 mL/min and a yield of approximately 12 mg of highly purified homo-Serlactone hPTHrp (1-34) peptide were:
1. Column equilibration in 50 mM KH-PO4, pH 6.5
2. Load 10 mL clarified supernatant (approximately 1.5 L culture broth or 2.4 g inclusion).
3. Wash column with 50 mM KH2PO4 pH 6.5 containing 50 mM NaCl until baseline is stabilized.
4. Elute column with 50 mM KH2PO4 pH 6.5 containing 90 mM NaCl.
Collect fractions for about 45 minutes.
5. Analyze the 90 mM NaCl fractions for homo-Serlactone hPTHrp (1- 34) content by C18 HPLC before pooling and storage.
Reverse Phase HPLC Chromatography.
A reverse phase Poros R/H 4.6 × 100 mm column (Perseptive Biosystems, Cambridge, MA) was used for the final purification step. The
chromatographic conditions were as follows: Mobile phase A: 0.1% trifluoroacetic acid (TFA) /water
B: 0.1% trifluoroacetic acid (TFA) /CH3CN
TIME FLOW % B
0 min 4 ml/min 15
5.0 min 4 ml/min 40
5.2 min 4 ml/min 100
6.8 min 4 ml/min 100
7.0 min 4 ml/min 15
Retention time of the homo-Serlactone hPTHrp (1-34), Compound 4, was approximately 2.943 minutes. The purified peptide was approximately 98% pure as determined by mass spectroscopy.
EXAMPLE XI The compounds of this invention were evaluated for their effect on bone mass in ovariectomized rats, generally in accord with the procedures of Gunness-Hey and Hock, Metab. Bone Dis. 5:177 181 (1984).
Adult Sprague-Dawley female rats were acclimatized, weight grouped (n
= 9, 10 or 12), and subjected to bilateral ovariectomy (OVX) or sham surgery. Dosing was initiated 17 days after surgery and continued for 20 days. Test compound was administered subcutaneously once a day in 2% rat serum/saline vehicle.
After 20 days of dosing, the rats were sacrificed and the right femurs excised. The femurs were cut in half and the distal half femurs (DHF) were further separated into trabecular bone (TB) and cortical bone
(CB) by drilling out the trabeculae. Calcium was extracted and measured by
Calcette calcium analyzer and expressed as mean bone Ca in mg/DHF/100 g body weight.
The two sample t-test was used to compare OVX and sham groups. Oneway ANOVA was used to compare OVX groups, followed by Fisher's LSD multiple comparison to compare each treatment group to vehicle.
Ovariectomy induced substantial total bone loss, primarily from trabecular bone. Total bone calcium was 47 to 54% lower than for shamoperated controls.
bPTH(1-34) and hPTHrp (1-34) at 80 μg/kg/day provided statistically significant increases in total bone calcium for treated OVX rats, ranging from 53 to 95% and 18 to 40%, respectively; however, there was no
significant increase in cortical bone calcium.
Compounds of this invention, dosed at 80 μg/kg/day, increased total bone calcium by from 66 to 138% and trabecular calcium by from 87 to 128%.
Cortical bone calcium, trabecular thickness, and bone volume were also significantly increased over untreated OVX controls. In this assay, the following compounds were tested:
Compound n Trabecular Bone Total Bone
Number (# of tests) Calcium Calcium
(% increase (% increase
over OVX) over OVX)
Compound 1 101-128% 88-138%
Compound 2 87-102% 66-114%
Compound 4 88-114%
In similar studies, ovariectomized rats were dosed for 5, 10 and 20 days, at 40 ug/kg/day, with the following results:
Compound n # Of Days (d) Total Bone
Number (# of tests) of dosing Calcium
(% increase over OVX)
Compound 1 3 20d 73-109%
Compound 4 5 20d 79-105%
Compound 4 1 lOd 79%
Compound 49 1 lOd 93%
Compound 4 1 5d 55%
Compound 42 1 5d 60%
EXAMPLE XII TOXICITY In the above Example XI, no toxic effects were observed with the compounds of the invention.

Claims

We claim:
1. A synthetic polypeptide analog of parathyroid hormone (PTH), parathyroid hormone related peptide (PTHrp) , or of a physiologically active truncated homolog or analog of PTH or PTHrp, or salt thereof, in which amino acid residues (22-31) form an amphipathic α-helix, said residues (2231) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa), ordered in the sequence :
Haa (Laa Laa Haa Haa), Laa.
2 . A polypeptide of claim 1, or salt thereof , in which amino acid residues (22 -31) form an amphipathic α-helix, the sequence of said residues (22 -31) selected from:
a) Xaa1 Xaa2 Leu Xaa4 Xaa5 Leu Xaa7 Xaa8 Xaa9 Xaa10 wherein
1 5 10
Xaa1 and Xaa4 are independently Glu, Glu (OCH3) , His, or Phe ; Xaa2 is Leu or
Phe ; Xaa5 is Lys or His ; Xaa7 and Xaa10 are independently Leu or Ile ; Xaa8 is
Ala, Arg, or Glu; and Xaa9 is Lys or Glu (SEQ ID NO: 26);
b) Xaa1 Xaa2 Leu Xaa4 Arg Leu Leu Xaa8 Arg Leu wherein
l 5 10
Xaa1 and Xaa4 are independently Glu, Glu (OCH3) , His , or Phe ; Xaa2 is Leu or
Phe ; Xaa8 is Glu, Lys, or Lys (COC^PEGX) and PEGX is a poly- (ethylene glycol methyl ether) radical of molecular
weight 100 to 10 , 000 (SEQ ID NO: 27);
c) Ala Leu Ala Glu Ala Leu Ala Glu Ala Leu (SEQ ID NO: 28);
1 5 10
d) Ser Leu Leu Ser Ser Leu Leu Ser Ser Leu (SEQ ID NO: 29);
1 5 10
e) Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu (SEQ ID NO: 30) .
1 5 10
3 . A polypeptide of claim 2 of the formula:
Xaa1 Xaa2 Xaa3 Xaa4 Xaa5 Xaa* Xaa7 Leu His Xaa10 Xaa11 Gly Xaa13 Ser Ile Gln Xaa17
Leu Xaa19 Xaa20 Xaa21 Xaa22-31 Xaa32 Xaa33 Xaa34 Xaa35 Xaa36 Xaa37 Xaa38 Term, wherein : Xaa1 is absent or is Ala;
Xaa2 is absent or is Val ;
Xaa3 is absent or is Ser;
Xaa4 is absent or is Glu or Glu (OCH3);
Xaa5 is absent or is His or Ala;
Xaa6 is absent or is Gln;
Xaa7 is absent or is Leu;
Xaa10 and Xaa17 are independently Asp or Asp (OCH3);
Xaa11 is Lys , Arg, or Leu;
Xaa13 is Lys, Arg, Tyr, Cys , Leu, Cys (CH2CONH (CH2) 2NH (biotinyl) ) , Lys (7-dimethylamino-2 -oxo-2H-l-berιxopyran-4 -acetyl) , or Lys (dihydrocinnamoyl); Xaa20 is Arg or Leu;
Xaa19 and Xaa21 are independently Lys, Ala, or Arg;
Xaa22-31 is selected from (SEQ ID NOS:26, 27, 28, 29, or 30); Xaa32 is His, Pro, or Lys;
Xaa33 is absent, or is Pro, Thr, Glu, or Ala;
Xaa34 is absent, or is Pro, Arg, Met, Ala, hSer, hSer lactone, Tyr, Leu, or 1,4-diaminobutyryl lactam;
Xaa35 is absent or is Pro, Glu, Ser, Ala, or Gly;
Xaa36 is absent or is Ala, Arg, or Ile;
Xaa37 is absent or is Arg, Trp, or 3-(-2-naphthyl)-L-alanine;
Xaa38 is absent or is Ala or hSer or Xaa38-42 is Thr Arg Ser Ala Trp;
and Term is OR or NR2 where each R is independently H, (C1-C4)alkyl or phenyl (C1-C4)alkyl; and the pharmaceutically acceptable salts thereof.
4. A polypeptide of claim 3 wherein Xaa22-31 is (SEQ ID NO:26) , and wherein Xaa11 and Xaa13 are both Lys; and Xaa19 and Xaa21 are both Arg.
5. The polypeptide of claim 4 which is :
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr Ala NH2 (SEQ ID NO: 7) .
6. The polypeptide of claim 4 which is:
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30 Leu Pro NH2 (SEQ ID NO:56) .
7. The polypeptide of claim 4 which is :
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr 1,4-diaminobutyryl lactam (SEQ ID NO: 63).
8. The polypeptide of claim 4 which is:
Ala Val Ser Glu His Gln Leu Leu His Asp Lys Gly Lys Ser Ile
1 5 10 15
Gln Asp Leu Arg Arg Arg Glu Leu Leu Glu Lys Leu Leu Glu Lys
20 25 30
Leu His Thr hSerlac (SEQ ID NO: 9) .
9. A pharmaceutical composition comprising an effective bone mass increasing amount of a polypeptide of claim 1, or salt thereof, in admixture with a pharmaceutically acceptable carrier.
10. A method for treating mammalian conditions characterized by decreases in bone mass, which method comprises administering to a subject in need thereof an effective bone mass increasing amount of a synthetic polypeptide analog of parathyroid hormone (PTH) , parathyroid hormone related peptide (PTHrp) , or of a physiologically active truncated homolog or analog of PTH or PTHrp, or salt thereof, in which amino acid residues (22-31) form an amphipathic α-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa) , ordered in the sequence:
Haa (Laa Laa Haa Haa)2 Laa.
11. A method of claim 10 in which the condition to be treated is osteoporosis.
12. A process for the solid phase synthesis of a polypeptide analog of PTH, PTHrp, or of a physiologically active truncated homolog or analog of PTH or PTHrp, or salt thereof, in which amino acid residues (22-31) form an amphipathic α-helix, said residues (22-31) selected from hydrophilic amino acids (Haa) and lipophilic amino acids (Laa), ordered in the sequence:
Haa (Laa Laa Haa Haa)2 Laa, which process comprises sequentially coupling protected amino acids on a suitable resin support, removing the side chain and Nα protecting groups, and cleaving the polypeptide from the resin support.
13. The use of a compound of Claim 1, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for the treatment of mammalian conditions characterized by decreases in bone mass, particularly, for the treatment of osteoporosis.
PCT/US1994/000589 1993-07-13 1994-01-21 Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis WO1995002610A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1993/006465 WO1994001460A1 (en) 1992-07-14 1993-07-13 Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis
USPCT/US93/06465 1993-07-13

Publications (1)

Publication Number Publication Date
WO1995002610A1 true WO1995002610A1 (en) 1995-01-26

Family

ID=22236755

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/000589 WO1995002610A1 (en) 1993-07-13 1994-01-21 Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis

Country Status (2)

Country Link
CN (1) CN1070500C (en)
WO (1) WO1995002610A1 (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040775A1 (en) * 1995-06-07 1996-12-19 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia
WO1997007815A2 (en) * 1995-08-29 1997-03-06 Syntex (U.S.A.) Inc. Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
EP0822200A1 (en) * 1996-07-30 1998-02-04 F. Hoffmann-La Roche Ag Synthesis of analogs of PTH and PTrP
WO1998004591A1 (en) * 1996-07-31 1998-02-05 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
WO1999012561A2 (en) * 1997-09-09 1999-03-18 F. Hoffman-La Roche Ag FRACTURE HEALING USING PTHrP ANALOGS
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
WO2003059291A2 (en) * 2002-01-10 2003-07-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US6921750B2 (en) 1995-07-13 2005-07-26 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US7994129B2 (en) 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9057727B2 (en) 2007-08-01 2015-06-16 The General Hospital Corporation Screening methods using G-protein coupled receptors and related compositions
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
EP2957278B1 (en) 2006-10-03 2017-05-17 Radius Health, Inc. A stable composition comprising pthrp and uses thereof
CN110114065A (en) * 2016-11-30 2019-08-09 珀杜研究基金会 Fracture-targeted bone regeneration by stimulation of parathyroid hormone receptors
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
US11782041B2 (en) 2017-04-28 2023-10-10 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931802B2 (en) * 2004-05-04 2012-05-16 メタボリック・ファーマシューティカルズ・リミテッド Methods for preventing or treating bone disorders
CN106146648B (en) * 2015-03-26 2020-06-12 深圳翰宇药业股份有限公司 Synthetic method of parathyroid hormone analogue
CN107375910B (en) * 2017-07-12 2020-03-24 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 Application of PTHrP in preparation of medicine for treating male hypogonadism syndrome

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451867A1 (en) * 1990-04-12 1991-10-16 Mitsubishi Chemical Corporation Parathyroid hormone antagonists
EP0477885A2 (en) * 1990-09-28 1992-04-01 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
WO1993006845A1 (en) * 1991-10-10 1993-04-15 Pang Peter K T PARATHYROID HORMONE ANALOGUES SUBSTITUTED AT aa?25,26,27¿ AND USE IN OSTEOPOROSIS TREATMENT
WO1994001460A1 (en) * 1992-07-14 1994-01-20 Syntex (U.S.A.) Inc. Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451867A1 (en) * 1990-04-12 1991-10-16 Mitsubishi Chemical Corporation Parathyroid hormone antagonists
EP0477885A2 (en) * 1990-09-28 1992-04-01 Takeda Chemical Industries, Ltd. Parathyroid hormone derivatives
WO1993006845A1 (en) * 1991-10-10 1993-04-15 Pang Peter K T PARATHYROID HORMONE ANALOGUES SUBSTITUTED AT aa?25,26,27¿ AND USE IN OSTEOPOROSIS TREATMENT
WO1994001460A1 (en) * 1992-07-14 1994-01-20 Syntex (U.S.A.) Inc. Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008024709A (en) * 1995-06-07 2008-02-07 Syntex Usa Inc Method for the treatment of corticosteroid induced osteopenia
WO1996040775A1 (en) * 1995-06-07 1996-12-19 Syntex (U.S.A.) Inc. Method for the treatment of corticosteroid induced osteopenia
US7632811B2 (en) 1995-07-13 2009-12-15 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
US6921750B2 (en) 1995-07-13 2005-07-26 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
USRE40850E1 (en) 1995-07-13 2009-07-14 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. Analogs of parathyroid hormone
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5969095A (en) * 1995-07-13 1999-10-19 Biomeasure, Inc. Analogs of parathyroid hormone
US7410948B2 (en) 1995-07-13 2008-08-12 Societe De Conseils De Recherches Et D'applications Scientifiques, Sas Analogs of parathyroid hormone
WO1997007815A2 (en) * 1995-08-29 1997-03-06 Syntex (U.S.A.) Inc. Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
WO1997007815A3 (en) * 1995-08-29 1997-09-18 Syntex Inc Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
US6849710B1 (en) 1996-07-30 2005-02-01 F. Hoffmann-La Roche Ag Method for the synthesis of analogs of parathyroid hormone and parathyroid hormone related peptide
KR100518982B1 (en) * 1996-07-30 2006-05-29 에프. 호프만-라 로슈 아게 Synthesis of analogues of parathyroid hormone and peptides associated with parathyroid hormone
EP0822200A1 (en) * 1996-07-30 1998-02-04 F. Hoffmann-La Roche Ag Synthesis of analogs of PTH and PTrP
US6362163B1 (en) 1996-07-31 2002-03-26 The General Hospital Corporation Parathyroid hormone-related peptide analogs
US6147186A (en) * 1996-07-31 2000-11-14 The General Hospital Corporation Parathyroid hormone-related peptide analogs
WO1998004591A1 (en) * 1996-07-31 1998-02-05 The General Hospital Corporation Novel parathyroid hormone-related peptide analogs
AU752925B2 (en) * 1997-09-09 2002-10-03 F. Hoffmann-La Roche Ag Fracture healing using PTHrP analogs
US6583114B2 (en) 1997-09-09 2003-06-24 Roche Palo Alto Llc Fracture healing using pthrp analogs
WO1999012561A3 (en) * 1997-09-09 1999-05-14 Hoffmann La Roche FRACTURE HEALING USING PTHrP ANALOGS
WO1999012561A2 (en) * 1997-09-09 1999-03-18 F. Hoffman-La Roche Ag FRACTURE HEALING USING PTHrP ANALOGS
KR100679778B1 (en) * 1997-09-09 2007-02-07 에프. 호프만-라 로슈 아게 FRACTURE HEALING USING PTHrP ANALOGS
US7015195B2 (en) 2002-01-10 2006-03-21 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
US7384912B2 (en) 2002-01-10 2008-06-10 Osteotrophin, Llc Treatment of bone disorders with skeletal anabolic drugs
WO2003059291A3 (en) * 2002-01-10 2005-03-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
WO2003059291A2 (en) * 2002-01-10 2003-07-24 Osteotrophin Llc Treatment of bone disorders with skeletal anabolic drugs
US7994129B2 (en) 2005-11-10 2011-08-09 Michigan Technological University Methods of using black bear parathyroid hormone
USRE49444E1 (en) 2006-10-03 2023-03-07 Radius Health, Inc. Method of treating osteoporosis comprising administration of PTHrP analog
EP2957278B1 (en) 2006-10-03 2017-05-17 Radius Health, Inc. A stable composition comprising pthrp and uses thereof
US9057727B2 (en) 2007-08-01 2015-06-16 The General Hospital Corporation Screening methods using G-protein coupled receptors and related compositions
US8987201B2 (en) 2009-12-07 2015-03-24 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US9492508B2 (en) 2010-05-13 2016-11-15 The General Hospital Corporation Parathyroid hormone analogs and uses thereof
CN110114065A (en) * 2016-11-30 2019-08-09 珀杜研究基金会 Fracture-targeted bone regeneration by stimulation of parathyroid hormone receptors
US11782041B2 (en) 2017-04-28 2023-10-10 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
US11835506B2 (en) 2017-04-28 2023-12-05 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same
US11977067B2 (en) 2017-04-28 2024-05-07 Radius Health, Inc. Abaloparatide formulations and methods of testing, storing, modifying, and using same

Also Published As

Publication number Publication date
CN1070500C (en) 2001-09-05
CN1127000A (en) 1996-07-17

Similar Documents

Publication Publication Date Title
EP0651765B1 (en) Analogs of pth and pthrp, their synthesis and use for the treatment of osteoporosis
US5977070A (en) Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
EP0835262B1 (en) Method for the treatment of corticosteroid induced osteopenia
WO1995002610A1 (en) Analogs of parathyroid hormone and parathyroid hormone related peptide: synthesis and use for the treatment of osteoporosis
US7595294B2 (en) Vasoactive intestinal polypeptide pharmaceuticals
US20060079456A1 (en) Vasoactive intestinal polypeptide pharmaceuticals
NO319848B1 (en) Synthetic peptide analogues for PTH and PTHrp, methods for solid phase synthesis thereof, pharmaceutical compositions comprising them, and use thereof for the manufacture of medicaments for the treatment of bone mass reductions.
MXPA98001630A (en) Pharmaceutical compositions of nasal administration of useful compounds for the treatment of osteoporo

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 94192745.8

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)